A Phase  1, Randomized,  Parallel -Group,  Double -Blind  Trial  of AV7909  (Liquid) 
and Thermostable AV7909 (Lyophilized) in Healthy Adult Volunteers  
 
DMID  Protocol  Number:  17-0093  
 
 
DMID  Funding  Mechanism:  Vaccine  and Treatment  Evaluation  Units  
 
 
Pharmaceutical  Support:  
Emergent  BioSolutions  
 
 
IND Sponsor:  Division  of Microbiology  and Infectious  Diseases,  National 
Institute of Allergy and Infectious Diseases, National Institutes of Health  
 
Lead Principal Investigator: [INVESTIGATOR_14407] D. Campbell, MD, MS 
DMID Clinical Project Manager: Onyinye Erondu, RN, MS 
DMID Medical Monitor: Jorge Mejia -Galvis, MD, MBA 
DMID  Medical  Officer:  Maryam  Keshtkar -Jahromi,  MD, MPH 
DMID Scientific Lead: Colleen Sico, ChemE MBA  
 
Version:  4.0 
11 July 2022  
 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
1  
  
STATEMENT  OF COMPLIANCE  
 
This trial will be carried  out in accordance  with Good  Clinical  Practice  (GCP)  as required  by [CONTACT_14504]:  
 
• United  States  (US)  Code  of Federal  Regulations  (CFR)  45 CFR  Part 46: Protection  of 
Human Subjects  
 
• Food and Drug Administration (FDA) Regulations, as applicable: 21 CFR Part 50 
(Protection of Human Subjects), 21 CFR Part 54 (Financial Disclosure by [CONTACT_1615]),  21 CFR  Part 56 (Institutional  Review  Boards),  21 CFR  Part 11, and 21 
CFR Part 312 (Investigational New Drug Application), 21 CFR 812 (Investigational 
Device Exemptions)  
 
• International Council for Harmonisation (ICH) E6(R2) Good Clinical Practice: 
Integrated  Addendum  to ICH E6(R1)  Guidance  for Industry,  published  in the Federal 
Register (83 Federal Register 8882 (2018)) and future revisions  
 
• Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects 
of Research,  Report  of the National  Commission  for the Protection  of Human  Subjects  of 
Biomedical and Behavioral Research  
 
• National  Institutes  of Health  (NIH)  Office  of Extramural  Research,  Research  Involving 
Human Subjects, as applicable  
 
• National  Institute  of Allergy  and Infectious  Diseases  (NIAID)  Clinical  Terms  of Award, 
as applicable  
 
• Applicable  Federal,  State and  Local  Regulations  and Guidance  
DMID  Protocol  17-[ADDRESS_1145137]  the study  in accordance  with the current  protocol  and will not make  changes  to 
the protocol without obtaining the sponsor’s approval and Institutional Review Board 
(IRB)/Institutional Ethics Committee (IEC) approval, except when necessary to protect the 
safety, rights, or welfare of subjects.  
 
Site Princ  ipal Investigator:   
 
Signed:    
Date:  
Name:   [INVESTIGATOR_14407]  D. Campbell,  MD, MS 
Title:  Principal  Investigator  
 
[CONTACT_122851]  17-[ADDRESS_1145138]  
Administration  ................................ ................................ ...............................  38 
5.2.5 Participant  Replacement  ................................ ................................ ................  38 
5.2.6 Termination  of Study  ................................ ................................ ....................  38 
6 Study  Intervention/Investigational  Product  ................................ ................................ ...........  [ADDRESS_1145139]  Storage  and Stability  Procedures  ................................ ...........  42 
Dosage, Preparation and Administration of Study Intervention/Investigational  
Product  ................................ ................................ ................................ ......................  42 
Accountability  Procedures  for the Study  Intervention/Investigational  Product  ........  43 

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
4  
 Assessment of Participant Compliance with Study Intervention/Investigational  
Product  ................................ ................................ ................................ ......................  44 
Concomitant  Medications/Treatments  ................................ ................................ ....... 44 
7 Study  Procedures/Evaluations  ................................ ................................ ...............................  45 
Clinical  Evaluations  ................................ ................................ ................................ .. 45 
Laboratory  Evaluations  ................................ ................................ .............................  46 
7.2.1 Clinical  Laboratory  Evaluations  ................................ ................................ .... 46 
7.2.2 Special  Assays  or Procedures  ................................ ................................ ........  48 
7.2.3 Specimen  Preparation,  Handling,  and Shippi[INVESTIGATOR_007]  ................................ ............  49 
8 Study  Schedule  ................................ ................................ ................................ ......................  51 
Screening  and Enrollment  Visits  ................................ ................................ ...............  51 
8.1.1 Visit  0, Screening  (Day  -28 to -2), Clinic  Visit  ................................ ............  51 
8.1.2 Visit  1, Day 1, Enrollment  (Vaccination),  Clinic  Visit  ................................ . 52 
Follow -up Visits  ................................ ................................ ................................ ........  54 
8.2.1 Visit 2, Day 8, Clinic Visit (End of Solicited Reactogenicity Period after  
First Vaccination)  ................................ ................................ ..........................  54 
8.2.2 Visit  3, Day 15, Clinic  Visit  (Second  Vaccination)  ................................ ...... 55 
8.2.3 Visit 4, Day 22, Clinic Visit (End of Solicited Reactogenicity Period after  
Second  Vaccination)  ................................ ................................ ......................  56 
8.2.4 Visit  5, Day 29, Clinic  Visit  ................................ ................................ ..........  57 
8.2.5 Visit  6, Day 64, Clinic  Visit  ................................ ................................ ..........  58 
(Window:  Day 60-68, inclusive)  ................................ ................................ ...............  58 
8.2.6 Visit  7, Day 195, Clinic  Visit  ................................ ................................ ........  58 
(Window:  Day 188 to 202, inclusive)  ................................ ................................ ....... 58 
Final  Visit  ................................ ................................ ................................ ..................  59 
8.3.1  Visit  8, Day 380, Clinic  Visit  ................................ ................................ ........  59 
(Window:  Day 373 to 387, inclusive)  ................................ ................................ ....... 59 
Early  Termination  Visit  (if needed)  ................................ ................................ ..........  59 
Unscheduled  Visit  (if needed)  ................................ ................................ ...................  [ADDRESS_1145140]  
Values  or Abnormal  Clinical  Findings  ................................ ..........................  70 
Reporting  Procedures  ................................ ................................ ................................  70 
9.3.1 Serious  Adverse  Events  ................................ ................................ .................  71 

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
5  
 9.3.2 Regulatory  Reporting  for Studies  Conducted  Under  DMID -Sponsored  IND 
.......................................................................................................................71  
9.3.3 Reporting  of Pregnancy  ................................ ................................ .................  72 
Type  and Duration  of Follow -up of Participants  after Adverse  Events  ....................  72 
Halting  Rules  ................................ ................................ ................................ .............  73 
9.5.1 Individual  Halting  Rules  ................................ ................................ ...............  73 
9.5.2 Study  Halting  Rules  ................................ ................................ ......................  73 
Safety  Oversight  ................................ ................................ ................................ ........  74 
9.6.1 Independent  Safety  Monitor  (ISM)  ................................ ...............................  74 
9.6.2 Safety  Monitoring  Committee  ................................ ................................ ....... 75 
10 Clinical  Monitoring  ................................ ................................ ................................ ...............  76 
Site Monitoring  Plan ................................ ................................ ................................ . 76 
11 Statistical  Considerations  ................................ ................................ ................................ ...... 77 
Introduction  ................................ ................................ ................................ ...............  77 
Study  Hypotheses  ................................ ................................ ................................ ...... 77 
Study  Outcome  Measures  ................................ ................................ ..........................  77 
Sample  Size Considerations  ................................ ................................ ......................  77 
11.4.1  Study  Population  ................................ ................................ ...........................  77 
11.4.2  Participant  Enrollment  and Follow -up ................................ ..........................  77 
11.4.3  Sample  Size ................................ ................................ ................................ ... 78 
Planned  Interim  Analyses  ................................ ................................ ..........................  80 
11.5.1  Interim  Safety  Review  ................................ ................................ ...................  80 
Final  Analysis  Plan ................................ ................................ ................................ .... 80 
11.6.1  Analysis  Populations  ................................ ................................ .....................  80 
12 Data  Collection  Forms  and Access  to Source  Data/Documents  ................................ ............  83 
13 Quality  Control  and Quality  Assurance  ................................ ................................ ................  85 
14 Ethics/Protection  of Human  Participants  ................................ ................................ ..............  [ADDRESS_1145141]  (IRB)  ................................ ................................ ..............  86 
Informed  Consent  Process  ................................ ................................ .........................  87 
Exclusion  of Women,  Minorities  and Children  (Special  Populations)  .....................  [ADDRESS_1145142]  Keepi[INVESTIGATOR_007]  ................................ ................................ ......................  93 
Data  Management  Responsibilities  ................................ ................................ ...........  93 
Data  Capture  Methods  ................................ ................................ ...............................  94 
Types  of Data ................................ ................................ ................................ ............  94 
Timing/Reports  ................................ ................................ ................................ ..........  [ADDRESS_1145143]  OF TABLES  
 
Table  1: Study  Objectives  and Outcome  Measures  ................................ ................................ ....... 13 
Table  2: Study  Groups  ................................ ................................ ................................ ...................  16 
Table  3: Venipuncture  Volumes  ................................ ................................ ................................ .... 48 
Table  4: Safety/Tolerability  Assessment  Timeline  ................................ ................................ ........  62 
Table  5: Injection  Site Reactogenicity  Grading  ................................ ................................ ............  62 
Table  6: Injection  Site Reactogenicity  Measurements  ................................ ................................ .. 63 
Table  7: Subjective  Systemic  Reactogenicity  Grading  ................................ ................................ . 63 
Table  8: Quantitative  Systemic  (Oral  Temperature)  Reactogenicity  Grading  ..............................  64 
Table  9: Pulse  and BP Adverse  Event  Grading  ................................ ................................ .............  64 
Table  10: Clinical  Safety  Laboratory  Adverse  Event  Grading…  ................................ .................  65 
Table  11: Probability  (%) to Detect  Safety  Events Emmes  ................................ ..........................  75 
Table  12: Precision  of Binomial  Confidence  Intervals  ................................ ................................ . 75 
Table  13: Minimum  Detectable  Difference  in the Probability  of Response  with 80% Power  ...... [ADDRESS_1145144]  OF FIGURES  
Figure  1: Schematic  of Study  Design  ................................ ................................ .............................  [ADDRESS_1145145]  OF ABBREVIATIONS  
 
 
AE Adverse  Event/Adverse  Experience  
AESIs  Adverse  Events  of Special  Interest  
ALT  Alanine  Aminotransferase  
AVA  Anthrax  Vaccine  Adsorbed  
AV7909  Anthrax  Vaccine  with CPG7909  Adjuvant  
β hCG Beta- human  Chorionic  Gonadotropin  (Pregnancy  Test)  
BMI Body  Mass  Index  
BP Blood  Pressure  
BUN  Blood  Urea  Nitrogen  
CFR Code  of Federal  Regulations  
CI Confidence  Interval  
CMS  Clinical  Materials  Services  
COI Conflict  of Interest  
CPG  7909  a CPG  oligodeoxynucleotide  adjuvant  
CpG55.2  a CPG  oligodeoxynucleotide  adjuvant  
Cr Creatinine  
CRP C-Reactive  Protein  
CROMS  Clinical  Research  Operations  and Management  Support  
CSR Clinical  Study  Report  
D Day(s)  
DNA  Deoxyribonucleic  Acid 
DCF  Data  Collection  Form  
DMID  Division  of Microbiology  and Infectious  Diseases,  NIAID,  NIH 
ECG  Electrocardiogram  
eCRF  Electronic  Case  Report  Form  
eClinical  Electronic  Data  Capture  System  
eMemory  Aid Electronic  Memory  Aid 
ELISA  Enzyme  Linked  ImmunoSorbent  Assay  
FDA  Food  and Drug  Administration  
FWA  Federal -Wide  Assurance  
GCP  Good  Clinical  Practice  
GMT  Geometric  Mean  Titer  
HBsAg  Hepatitis  B surface  Antigen  
HCV  Hepatitis  C Virus  
HEENT  Physical  Exam  of the Head,  Eyes,  Ears,  Nose,  and Throat  
Hgb Hemoglobin  
HIPAA  Health  Insurance  Portability  and Accountability  Act 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
10  
  
HIV Human  Immunodeficiency  Virus  
HLGT  High  Level  Group  Term  
HRPO  Human  Research  Protections  Office  
IATA  International  Air Transport  Association  
ICF Informed  Consent  Form  
ICH International  Council  for Harmonisation  
IgG Immunoglobulin  G 
IM Intramuscular(ly)  
IND Investigational  New  Drug  
IRB Institutional  Review  Board  
ISM Independent  Safety  Monitor  
IU/L International  Unit(s)  per Liter  
LLOQ  Lower  Limit  of Quantitation  
MAAE  Medically -Attended  Adverse  Event  
MedDRA Medical  Dictionary for  Regulatory  Activities  
mg/dL  Milligrams  per Deciliter  
mITT  Modified  Intent -to-Treat  
mL Milliliter(s)  
mm³ Cubic Millimeter(s)  
MOP  Manual  of Procedures  
N Number  of Subjects  
NIAID  National  Institute  of Allergy  and Infectious  Diseases,  NIH,  DHHS  
NIH National  Institutes  of Health  
OAC  Office  of Accountability  and Compliance  
ODNs  Synthetic  oligodeoxynucleotides  
OER  Office  of Extramural  Research  
OHRP  Office  for Human  Research  Protections  
PHI Personal  (Protected)  Health  Information  
PA Protective  Antigen  
PI [INVESTIGATOR_825776] -Mediated  Medical  Conditions  
PP Per Protocol  
QA Quality  Assurance  
QC Quality  Control  
RF Rheumatoid  Factor  
SAE Serious  Adverse  Event/Serious  Adverse  Experience  
SAP Statistical  Analysis  Plan 
SDCC  Statistical  and Data  Coordinating  Center  
DMID  Protocol  17-[ADDRESS_1145146]  Upper  Limit  of Normal  
UMB  University  of Maryland,  Baltimore  
US United  States  
V Visit(s)  
VTEU  Vaccine  and Treatment  Evaluation  Unit 
WHO  World  Health  Organization  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
12  
  
PROTOCOL  SUMMARY  
 
 
Title:  A Phase  1, Randomized,  Parallel -Group,  Double -Blind  Trial  of AV7909 
(Liquid) and Thermostable AV7909 (Lyophilized) in Healthy Adult 
Volunteers  
Phase:  I 
Population:  40 males  and non-pregnant  females,  18 to 45 years  of age, inclusive, 
who are in good health and meet all eligibility criteria  
Number  of Sites:  1 Vaccine  and Treatment  Evaluation  Unit (VTEU)  
Study Duration:  Approximately  [ADDRESS_1145147]  Participation  Duration:  Approximately  13 months  
Estimated  Time  to Complete 
Enrollment:  Approximately6  months  
Description  of Agents:  • AV7909  liquid  formulation  vaccine  
• AV7909  lyophilized  formulation  vaccine  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
13  
  
Table  1: Study  Objectives  and Outcome  Measures  
Primary  Objective:  Safety  Primary  Safety  Outcome  Measures  
• To assess  the safety  of lyophilized  and 
liquid formulations of AV7909.  • Occurrence  of all SAEs  through  approximately  12 
months following receipt of the second study 
vaccination (approximately Day 380).  
• Occurrence  of abnormal  clinical  safety  laboratory 
AEs at approximately Day 29.  
• Occurrence of all protocol specified AESIs (i.e., 
PI[INVESTIGATOR_106279])  and MAAEs,  from  the time of the first 
study vaccination through approximately 12 
months following the second vaccination 
(approximately Day 380).  
• Occurrence of unsolicited non -serious adverse 
events  from  the time of the first study  vaccination 
through approximately Day 64.  
Primary  Objective:  Tolerability  Primary  Tolerability  Outcome  Measures  
• To assess  the tolerability  of lyophilized  and 
liquid formulations of AV7909.  • Occurrence  of solicited  injection  site and systemic 
reactogenicity events in the week after each  study 
vaccination (Days 1 through 8 and Days 15 
through 22, inclusive).  
Secondary  Objective:  Immunogenicity  Secondary  Immunogenicity  Outcome  Measures  
• To obtain initial estimate of comparative 
immunogenicity  of liquid  and lyophilized 
formulations of AV7909.  • Geometric mean titer and 95% confidence 
intervals of antibodies assayed by [CONTACT_825804] (ED 50 and NF 50) and anti-PA 
IgG by [CONTACT_825805]  8, 15, 22, 
29, 64, 195, and 380.  
• Proportion and 95% confidence intervals of 
participants in each study group with 
seroconversion for antibodies detected by [CONTACT_825806] (defined as a ≥4 -fold increase over 
baseline levels, or a ≥4 -fold increase over the 
lower limit of quantification [LLOQ ] if the 
baseline  value  is < LLOQ)  on approximately  Days 
8, 15, 22, 29, 64, 195, and 380.  
 
• Proportion and 95% confidence intervals of 
participants in each study group with putative 
seroprotection (defined as NF 50 ≥ 0.56) before 
vaccination  and on approximately  Days  8, 15, 22, 
29, 64, 195, and 380. 
Exploratory  Immunogenicity  Objectives  Exploratory  Immunogenicity  
Study  Outcomes  
• None  • None  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
14  
  
Description  of Study 
Design:  The study is a phase I randomized, parallel -group, double -blind controlled 
interventional trial in which the safety, tolerability, and immunogenicity of 2 
formulations of adjuvanted anthrax vaccine (AV7909), lyophilized and liquid, 
both manufactured by [CONTACT_628999], will be assessed and compared. 
AV7909 is an investigational vaccine that combines the currently licensed 
Anthrax Va ccine Adsorbed (AVA, BioThrax) with the adjuvant CPG 7909, an 
oligonucleotide. Forty healthy young adults, 18 to 45 years old, inclusive, who 
meet  all eligibility  criteria,  will be randomly  allocated  to one of two study  groups 
in a 1:1 ratio: [ADDRESS_1145148]. Stratification by [CONTACT_825807] (18 -30 years) and 
older (31 -45 years) males and females are  assigned to each vaccine. The  
vaccines will be given intramuscularly in a 2 -dose schedule, 2 weeks apart. Data 
entry will be “direct”, that is, without the significant use of paper source 
documents or case report forms. Participants will be followed for s afety and 
tolerability by [INVESTIGATOR_2993] -person visits, electronic reactogenicity records (eMemory 
Aids), and safety laboratory values. A Safety Monitoring Committee will 
evaluate the safety data if halting rules are met or if deemed necessary by [CONTACT_825808]. Immunogenicity will be evaluated by [CONTACT_094] - 
vaccination and multiple post -vaccination assessments of toxin -neutralizing 
antibodies and IgG anti -PA antibodies assayed by [CONTACT_825809] (ELISA) over approximately one year. P articipants will 
be followed for 1 year following the second dose of vaccine.  
Safety will be assessed by [CONTACT_825810], non -serious 
unsolicited Adverse Events, Serious Adverse Events (SAEs), Medically 
Attended Adverse Events (MAAEs), and Adverse Events of Special Interest 
(AESIs),  which,  for this protocol,  are defined  as Potentially  Immune -Mediated 
Medical Conditions  (PI[INVESTIGATOR_106279]). Unsolicited non -serious adverse events (AEs) 
will be collected from Day 1 through approximately Day 64, inclusive. SAEs, 
MAAEs, and AESIs (PI[INVESTIGATOR_106279]) will be collected from the time of study 
vaccination through approximately Day 380. Clinical safety laboratory 
evaluations will be performed at screening and at approximately Day 29  
Reactogenicity will be  measured  by [CONTACT_825811] (Days 1 through 8 
and target of Days 15 through 22, inclusive). Any reactogenicity events that 
persist on Day [ADDRESS_1145149]  access  to the study  codes;  all other  study  personnel and  the participants 
will be blinded.  
Immunogenicity  testing  will include  performing  serological  assays  to assess  
toxin neutralizing antibodies (reported as ED 50 and NF 50) and IgG anti -PA 
antibodies  assayed  by [CONTACT_825812]  (ELISA) prior  to 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
15  
  
vaccination  (on Day 1) and on approximately Days  8, 15, 22, 29, 64, 195, and 
380. 
16  
 DMID  Protocol  17-0093  Version  4.0 
Anthrax  AV7909  Liquid  vs Lyophilized  11 Jul  2022  
 
 
Table  2: Study  Groups  
 
  Day 1 Day 15 
Study Group  N Study  Vaccine  Study  Vaccine  
1 20 AV7909  liquid  AV7909  liquid  
2 20 AV7909  lyophilized  AV7909  lyophilized  
Total  40   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
17  
  
Figure  1: Schematic  of Study  Design  
 
 
 
 
 
 
Immunogenicity  evaluated  by [CONTACT_094]-vaccination  and post-vaccination 
assessments.  
Participants  followed  for safety  and tolerability  by [INVESTIGATOR_2993]-person  visits.  
 
 
 
 
 
 
 
 
 
 
Vaccination:  
1 of 2 formulations 
of adjuvanted 
anthrax vaccine 
(AV7909)  
Enrollment:  
Eligible  participants  randomly  allocated  1:1 to one of two study  groups  
Screen  for eligibility  
N= [ADDRESS_1145150].  N=[ADDRESS_1145151].  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
18  
  
1 KEY  ROLES  
 
 
Principal  Investigator:  [INVESTIGATOR_14407]  D. Campbell,  MD, MS 
University  of Maryland  School  of Medicine 
Center for Vaccine Development  
Baltimore, MD [ADDRESS_1145152]  Manager:  Onyinye  Erondu,  RN, MS 
Division  of Microbiology  and Infectious  Diseases 
NIAID, NIH  
DMID  Medical  Monitor:  Jorge  Mejia -Galvis,  MD, MBA  
Division  of Microbiology  and Infectious  Diseases 
NIAID, NIH  
DMID  Medical  Officer:  Maryam  Keshtkar -Jahromi,  MD, MPH  
Division  of Microbiology  and Infectious  Diseases 
NIAID, NIH  
DMID  Scientific  Lead:  Colleen  Sico,  ChemE  MBA  
Division  of Microbiology  and Infectious  Diseases 
NIAID, NIH  
Safety  and Pharmacovigilance:  DMID  Pharmacovigilance  Group  
Clinical  Research  Operations  and Management  Support 
(CROMS)  
Site Principal  Investigators:  Not applicable  (This  is a single  site study.)  
 
Statistical  and Data  Coordinating 
Center:   
The Emmes  Company,  LLC 
Clinical  Materials  Services:  Fisher  BioServices  
 
Central  (Clinical)  Laboratory:   
Garcia  Laboratory  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
19  
  
 
Anthrax  Toxin  Neutralization  and 
ELISA  Serological  Assays 
Laboratory:  Battelle  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
20  
  
2 BACKGROUND  INFORMATION  AND  SCIENTIFIC 
RATIONALE  
 
Background  Information  
 
Bacillus anthracis is an aerobic, spore‑forming, gram‑positive bacterium that causes the disease 
anthrax in animals and people. Zoonotic anthrax still occurs in many parts of the world but is 
completely controlled in the [LOCATION_002] as a result of animal vaccination programs and other 
measures, although sporadic cases of anthrax are reported after exposure to imported animal 
hides.[ADDRESS_1145153] of bioterror because it is easy to cultivate, easy to weaponize, easy to 
distribute, and has a high case fatality rate.2 
The anthrax vaccine that is currently licensed in the US, Anthrax Vaccine Adsorbed (AVA, 
BioThrax ™) is produced from the culture filtrate of an attenuated, toxigenic strain of B. 
anthracis , and contains Protective Antigen (PA, the binding domain of the anthrax toxin), small 
amounts  of other  anthrax bacterial  products,  the adjuvant  aluminum  hydroxide  (Alhydrogel),  the 
stabilizer formaldehyde, and the preservative benzethonium chloride. This vaccine is highly 
protective against inhalational B. anthracis spore  challenge in rabbits and monkeys 4. A similar 
vaccine had 92%  efficacy against clinical anthrax among workers in New England wool mills in 
the middle  of the last century,[ADDRESS_1145154]  ever been  performed.  The 
vaccine is recommended as pre‑exposure prophylaxis for members of the US Armed Forces, for 
some laboratory workers, some “first responders”, and for others who may be occupationally 
exposed.[ADDRESS_1145155]‑exposure in 
conjun ction with antibiotics.[ADDRESS_1145156] adjuvant CPG 79 09 to the currently 
licensed vaccine. This new vaccine, named AV7909, is being developed by [CONTACT_825813] a vaccine with an indication for postexposure pro phylaxis (PEP) that is intended 
to decrease  the risk of anthrax  disease  after exposure.  AV7909  has been  shown  to be safe and has 
improved immunogenicity when compared to AVA.7-[ADDRESS_1145157] of bioterror is stored in the National Strategic 
Stockpi[INVESTIGATOR_5829], a thermostable (lyophilized) formulation of the AV7909 adjuvanted anthrax vaccine 
would offer many advantages to a liquid formulation.  
 
The proposed  trial will assess,  in healthy  adults,  the safety,  reactogenicity,  and immunogenicity 
of the thermostable lyophilized formulation of AV7909 compared to the liquid formation of 
AV7909.  
 
Potential  Risks  and Benefits  
 
2.3.1 Potential  Risks  
 
The potential  risks  of participating  in this trial are those  that may occur  due to blood  drawing,  the 
IM injection itself, reactions to the vaccines, and breach of confidentiality.  
 
Phlebotomy Risks.  Drawing blood is typi[INVESTIGATOR_452338]. It often causes 
transient  mild discomfort.  Approximately  2% of persons  who have  blood  drawn  will experience 
“near syncope”, in which they feel lightheaded or have other symptoms, but do not lose 
consciousness. Syncope (fainting) is a transient autonomic (vasovagal) response to phlebotomy 
that occurs in approximately 1% of blood donors and fewer than 1% of those having diagnostic 
phlebotomy.10 It is managed by [CONTACT_825814], loosening his or her clothes,  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
22  
  
monitoring vital signs, reassuring the participant, and giving fluids. Minor bruising at the blood 
draw site may occur in up to 12% and a hematoma in 2 -3%. These events can be prevented or 
decreased in frequency by [CONTACT_825815] c an be ameliorated, when 
they occur, by [CONTACT_452387]. Rarely, following 
phlebotomy, persons may have nerve injury (typi[INVESTIGATOR_452339]) causing pain, 
paresthesia, and motor or sensory loss. This phe nomenon is uncommon and typi[INVESTIGATOR_825777].[ADDRESS_1145158] of the deltoid can 
lead to injury of the bursa, which can cause Shoulder Injury Rel ated to Vaccine Administration, 
or SIRVA.12 Proper  education  and technique  reduce  the risk of adverse  events  after IM injection.  
Vaccine Administration Risks.  The risk profile for AVA (BioThrax) is well known, given that 
millions  of persons  have  been  vaccinated.  The risks  of AV7909  are less well characterized,  given 
that fewer persons have been vaccinated with this product.  
 
Risks  of AVA  (BioThrax).  Since  the licensure  of BioThrax  in 1970,  more  than 3.[ADDRESS_1145159]  common  (≥ 10%)  local  (injection -site) adverse  reactions  observed  in 
clinical  studies  are tenderness,  pain,  erythema,  edema,  and arm motion  limitation.  The most 
common  (≥ 5%) systemic  adverse  reactions  are muscle  aches,  headache,  and fatigue.  
 
Risks  of CPG  [ADDRESS_1145160] been evaluated  as vaccine  adjuvants, 
including  CPG1018,  the adjuvant  in Heplisav -B, a hepatitis  B vaccine  now licensed  in the US for 
persons 18 years and older.  
 
Risks  of AV7909.  Emergent  BioSolutions  has sponsored  three  completed  clinical  studies  in 
healthy  participants  18 through  50 years  of age as part of the AV7909  development  program:  a 
phase  1, a phase  1/2, and a phase  [ADDRESS_1145161]  been  exposed  to a 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
23  
  
combination  of AVA  and CPG7909.  In the initial  trial, a formulation  with AVA  + 1.[ADDRESS_1145162]  increased  frequency  and severity  of 
local  and systemic  reactions  in the AV7909  formulation  compared  to BioThrax.9 The second  trial 
identified  a formulation  of AV7909  with a lower  CPG7909  concentration  (0.25  mg CPG  7909)  for 
further  clinical  development  that produced  an enhanced  immune  response  without  increased 
reactogenicity.  7 This formulation  was evaluated  in the phase  2 trial described  below  and is the 
formulation to be tested in the current study.  
 
In 2014,  a phase  2, randomized,  double -blinded,  BioThrax -controlled  study  was conducted  to 
evaluate  the safety  and immunogenicity  of 3 IM vaccination  schedules  and 2 dose levels  of 
AV7909  in 168 healthy  adults.13 The results  of this study  found  that AV7909  was well tolerated: 
4.2%  of subjects  discontinued  vaccination  due to AEs;  no serious  adverse  events  (SAEs)  were 
reported  that were  potentially  vaccine  related;  no reported  AEs of potential  autoimmune  etiology 
were  reported.  The vaccine  produced  a more  rapid  immune  response  compared  to BioThrax as 
measured  by [CONTACT_825816] 50 values≥0.56  (a putative  correlate  of protection)  obtained  through  Day 63. 
 
Hypersensitivity  and Anaphylactic/Anaphylactoid  Reactions.  Parenteral  administration  of any 
protein  product  may be associated  with immediate -type hypersensitivity  reactions  that can manifest 
as urticaria,  shortness  of breath,  wheezing,  nausea  and crampi[INVESTIGATOR_007],  and in severe  cases,  hypotension. 
Acute  allergic  reactions,  including  anaphylaxis,  have  occurred  with BioThrax.  Reports  of 
hypersensitivity,  urticaria,  and pruritus  have  rarely  occurred  following  administration  of AV7909. 
Appropriate  medical  treatment  and supervision  will be available  to manage  possible  anaphylactic 
reactions  following  administration  of the vaccine  and the vaccine  will not be administered  to 
participants  with known  sensitivity  to any of the vaccine  components,  e.g., synthetic 
oligodeoxynucleotides  (ODNs),  formaldehyde,  benzethonium  chloride  (phemerol),  or aluminum.  
The vaccine  stoppers  do not contain  latex.  
 
Potentially  Immune  Mediated  Medical  Conditions  (PI[INVESTIGATOR_106279]) . There  is a plausible  potential  for 
CPG  ODN  adjuvants  to trigger  autoimmune  disease  in susceptible  individuals  14, possibly  as a 
result  of non-specific  activation  of T or B lymphocytes.  No participants  in completed  AV7909 
clinical  trials  have reported  AEs related  to autoimmune  disorders.  Additionally,  no AEs suggestive 
of autoimmune  disease  have  been  reported  in the reviewed  published  data on the CPG  7909 - 
adjuvanted  infectious  disease  vaccine  trials.  A number  of these  trials  reported  participants  with 
moderate,  transient  elevations  above  the normal  range  of anti-double  stranded  deoxyribonucleic 
acid (anti-dsDNA)  antibody  values  or positive  antinuclear  antibody  (ANA)  or mild elevations  in 
rheumatoid  factor  (RF)  following  vaccination,  which  typi[INVESTIGATOR_825778].15-[ADDRESS_1145163] dose of vaccine,  the incidences  of new onset 
immune -mediated  AEs (as reviewed  by [CONTACT_825817])  were  not clinically  different  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
24  
  
between  the Heplisav -B group  (0.1%;  4/5587)  and the non-adjuvanted  Engerix -B group  (0%; 
n=2781),  nor were  these  AEs in the Heplisav -B group  considered  related  to vaccination.  
 
In oncology  trials  of CPG  7909,  which  typi[INVESTIGATOR_825779]7909  vaccine  exposure,  autoimmune  disease  has been reported  in multiple 
participants,  although  causal  attribution  to the study  product  has been  complicated  by 
[CONTACT_825818]/therapi[INVESTIGATOR_014].  The autoimmune  conditions  observed  have 
included  polyarthralgia,  arthritis,  Sjögren’s  Syndrome,  autoimmune  thyroiditis,  vitiligo,  Guillain - 
Barré syndrome, and ulcerative colitis.  
 
Because  of this potential  risk, individuals  with a history  of autoimmune  disorders  or active 
autoimmune  disease  (PI[INVESTIGATOR_106279])  will be ineligible  for this trial. Additionally,  because  of the 
possibility  of a delay  between  the vaccination  and onset  of symptoms  indicative  of a disease 
process  of this kind,  all participants  will be followed  for PI[INVESTIGATOR_825780] (for 12 
months  after the second  vaccination,  to approximately  Day 380).  PI[INVESTIGATOR_825781] 
“Adverse  Events  of Special  Interest”  (AESI).  Blood  samples  will be collected  before  vaccination 
from  all participants  for possible  laboratory  evaluation  should  suspi[INVESTIGATOR_271233] a PI[INVESTIGATOR_825782].  Participants  who discontinue  study  treatment  will be encouraged  to attend  all 
subsequent  clinic  visits  and safety  follow -up contacts  to facilitate  this monitoring.  
 
Local  Reactogenicity . During  clinical  testing  in which  241 participants  were  exposed  to the 
combination  of BioThrax  + CPG  7909,  the most  common  local  reactions  were  mild to moderate 
pain,  tenderness,  and arm motion  limitation.  These  reactions  often  resolved  within  [ADDRESS_1145164]  common  local  AEs (reported  in ≥ 5% of participants  in at least one of the 
AV7909  arm(s)  from  the three  completed  clinical  trials)  included  injection  site pain,  arm 
movement  impairment,  warmth,  edema/induration,  erythema,  hemorrhage,  and pruritus.  
 
Systemic  Reactogenicity . During  clinical  testing  to date,  in completed  trials  in which  participants 
were  exposed  to the combination  of BioThrax  + CPG  7909,  systemic  reactogenicity  manifested 
primarily  as mild to moderate  fatigue,  muscle  ache,  and headache.  The most  common  systemic 
AEs (reported  in ≥ 5% of participants  in at least one of the AV7909  arm(s)  from  the three 
completed  clinical  trials)  included  fatigue,  myalgia,  headache,  respi[INVESTIGATOR_825783],  pyrexia, 
pharyngolaryngeal  pain,  nausea,  upper  respi[INVESTIGATOR_2826],  and chills.  
 
Laboratory  Findings.  During  clinical  testing  to date, in completed  trials  in which  participants  were 
exposed  to the combination  of BioThrax  + CPG  7909,  the most  common  reported  laboratory 
findings  after vaccination  were  hypokalemia,  lymphocyte  count  decreased,  leukopenia, 
hypoglycemia,  blood  creatine  phosphokinase  increased,  and hemoglobin  decreased.  
 
Pregnancy  and Lactation . No reproductive  toxicity  studies  have been performed  with AV7909. 
BioThrax  can cause  fetal harm  when  administered  to a pregnant  woman.  CPG  7909  has been  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
25  
  
determined  to be embryolethal  in rabbits  and teratogenic  in developi[INVESTIGATOR_825784]7909  (0.25  mg). In rats, fetal skeletal  anomalies 
were  noted  when  administered  at a dose of > 3 mg/kg/day;  in rabbits,  slightly  reduced  numbers  of 
viable  fetuses  were  noted  when  administered  at a dose of 3 mg/kg/day,  and external,  visceral,  and 
skeletal  malformations occurred when administered at >1  mg/kg/day.  
 
Given  these  findings,  breastfeeding  or a positive  pregnancy  test will preclude  study  enrollment.  All 
women  of childbearing  potential  will have  a negative  pregnancy  test before  each vaccine 
administration  and will agree  to use effective  contraception  from  at least one month  prior  to Day 1 
and continued  through  Day 75 (60 days after second  vaccination).  Confirmed  pregnancy  will result 
in discontinuation of vaccinations.  Participants who become  inadvertently  pregnant  during  the trial 
will be monitored  for pregnancy  outcomes,  if the participant  provides  permission,  according  to 
protocol -specified procedures.  
 
Risk of loss of privacy or confidentiality.  Participants will be asked to provide, in a private 
setting, Personally Identifying Information (PII) and Protected Health Information (PHI). All 
attempts will be made to keep PII and PHI confidential within the limits of the law. However, 
there is a chan ce that unauthorized persons will gain access to a participant’s PII or PHI.  All 
hard copy  research  records  will be kept in a locked file  cabinet  or maintained  in a locked  room at 
the participating VTEU site.  Electronic files and access to the central clinical and laboratory 
websites  at which  study -related  data are  stored will  be password  protected.  Only  people  who are 
involved  in the conduct,  oversight,  monitoring,  or auditing  of this study  will be allowed  access  to 
the confidential information that is collected.  Any publications from this study will not use 
information that will identify participants by [CONTACT_2300].  Organizations that may inspect and/or copy 
research records maintained at the participating VTEU site for quality assurance and data 
analysis include groups such as National Institute of Allergy and Infectious Diseases (NIAID) 
and the Food and Drug Adminis tration (FDA) and their contractors. They also include the 
Human Research Protections Office (HRPO) at the University of Maryland, Baltimore (UMB) 
and its Institutional Review Board (IRB), and the Office of Accountability and Compliance 
(OAC) at UMB.  
 
Unknown  risks . There  may be unknown  risks,  discomforts,  or side effects.  
 
2.3.[ADDRESS_1145165] benefits, participants may contribute to a societal benefit through the  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
26  
  
improvement  of our understanding  of these  vaccines  and by [CONTACT_825819].  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
27  
  
3 STUDY  OBJECTIVES  AND  OUTCOME  MEASURES  
 
Refer  to Table  1: Study  Objectives  and Outcome Measures  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
28  
  
4 STUDY  DESIGN  
 
The study is a phase I randomized, parallel -group, double -blind controlled interventional trial in 
which the safety, tolerability, and immunogenicity of 2 formulations of adjuvanted anthrax 
vaccine  (AV7909),  lyophilized  and liquid,  both manufactured  by [CONTACT_628999],  will be 
assessed and compared. AV7909 is an investigational vaccine that combines the currently 
licensed Anthrax Vaccine Adsorbed (AVA, BioThrax) with the adjuvant CPG 7909, an 
oligonucleotide. Forty healthy young adults, 18 to 45 years  old, inclusive, who meet all 
eligibility criteria, will be randomly allocated to one of two study groups in a 1:1 ratio: [ADDRESS_1145166]. Stratification by [CONTACT_825820] (18 -30 years) and older (31 -45 years) males and females will be assigned to each 
vaccine. The vaccines will be given intramuscularly in a 2 -dose schedule, 2 weeks apart. Data 
entry will  be “direct”, that is,  without the significant use of  paper source  documents. Participants 
will be followed for safety and tolerability by [INVESTIGATOR_2993] -person visits, electronic reactogenicity records 
(eMemory  Aids),  and safety  laboratory  values.  A Safety  Monitoring  Committee  will evaluate  the 
safety data whenever necessary (as determined by [CONTACT_434136]) and in 
the event of a halting rule occurring. Immunogenicity will be evaluated by [CONTACT_094] -vaccination and 
multiple post -vaccination assessments of toxin -neutralizing antibodies as determined by [INVESTIGATOR_6679] [ADDRESS_1145167] PA measured by [CONTACT_6428]. Participants will be followed 
for 1 year following the second dose (through approximately Day 380).  
 
Safety will be assessed by [CONTACT_825821] -serious unsolicited Adverse Events, Serious 
Adverse Events (SAEs), Medically Attended Adverse Events (MAAEs), Adverse Events of 
Special Interest (AESIs) [the AESIs collected in this study are Potentially Immune -Mediated 
Medical  Conditions  (PI[INVESTIGATOR_106279])],  and by [CONTACT_825822].  SAEs,  MAAEs,  and AESIs  will 
be collected from the time of study vaccination through approximately Day 380. Non -serious 
unsolicited AEs will be collected from Day 1 to Day 64, inclusive. Clinical laboratory 
evaluations for eligibility will be the following: specific hematology parameters, chemistry 
parameters, , specific urine tests for drugs of abuse, and hemoglobin A 1C. Also, an 
electrocardiogram will be performed at screening and reviewed by [CONTACT_825823]. The cardiologist will determine if any findings on the electrocardiogram are 
significant and thereby [CONTACT_825824]. At approximately Day 29, laboratory tests for hematology 
and chemistries will be repeated.  
 
Reactogenicity will be measured by [CONTACT_825825] (Days 1 through 8 and target of Days 15 
through  22, inclusive).  The window  for dose [ADDRESS_1145168] on Day 8 or Day 22 (or the final  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
29  
  
day of the second reactogenicity period) will be followed until resolution.  Only pharmacy 
personnel,  the Emmes  unblinded  team,  and an unblinded  vaccinator  and checker  will have  access 
to the study codes; all other study personnel and all participants will be blinded.  
 
Immunogenicity testing will include performing serological assays to assess for toxin 
neutralizing antibodies (reported as ED 50 and NF 50), the gold standard assay for assessing 
response  and protection  following  anthrax  vaccines,  prior  to vaccination  and on approximately 
Days 8,  15, 22, 29, 64, 195, and 380. Should the  second dose  of vaccine be given after Day 15 
(the acceptable window is Days 15 to 18, inclusive) the remainder of the study schedule days 
shift accordingly,  to maintain  the intervals  in the schedule.  In addition,  anti-PA IgG antibodies 
will be measured by [CONTACT_825826], on those same days.  
 
For additional  details  on study  procedures  and evaluations  and the  study  schedule  by [CONTACT_122799]/days,  see Sections  7 and 8 as well as Appendix  A: Schedule  of Study  Procedures  and 
Evaluations and Appendix B : Adverse Events of Special Interest.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
30  
  
5 STUDY  ENROLLMENT  AND  WITHDRAWAL  
 
Forty (40) males and non -pregnant females, [ADDRESS_1145169] the community at large at the participating VTEU site, but in order to assure 
enrollment of near equal numbers in each study group (AV7909 Liquid and AV7909 
Lyophilized)  by [CONTACT_825827],  a stratified  enrollment  procedure  will be employed.  The 
strata used will be males/females and age 18 -30 years/age [ADDRESS_1145170] previously participated in vaccine trials, other than anthrax 
vaccine trials, conducted at the VTEU site. Other forms and/or mechanisms of recruitment may 
also be used. The IRB will approve the recruitment proces s and all materials prior to use.  
 
Participant inclusion and exclusion criteria will be  assessed by a  study clinician licensed to make 
medical  diagnoses  and listed  on the Form  FDA  1572  as the site principal  investigator (PI)  or sub- 
investigator.  
 
No exemptions are granted on participant inclusion or exclusion criteria in DMID -sponsored 
studies.  Questions  about  eligibility  will be directed  toward  the DMID  Medical  Officer  for this 
trial. 
 
Eligibility  Criteria  
 
5.1.[ADDRESS_1145171]  meet  all the following  inclusion  criteria:  
 
1. Provide  written  informed consent prior  to initiation  of any study  procedures.  
 
2. Understand  and comply  with planned  study  procedures,  including  completion  of the 
electronic memory aid, and be available for all study visits.  
 
3. Agree  to the collection  of venous  blood,  per protocol.  
 
4. Have  adequate  venous  access  for phlebotomies.  
 
5. Be a male  or non-pregnant  female,  [ADDRESS_1145172] 90 days, 
should be stable (not worsening) for the last 60 days (no hospi[INVESTIGATOR_602], emergency room or urgent care for 
condition,  or invasive medical  procedure and no adverse symptoms that  need medical intervention such as  medication 
change indicative of worsening/supplemental oxygen). This includes no change in chronic prescripti on medication, 
dose or frequency, indicative of  worsening disease, in the 60 days prior to enrollment. Any prescription change that  is 
due to change of health care provider, insurance company, etc., or that is done for financial reasons, will not be 
considered  a deviation  of this inclusion  criterion. Participants may  be on chronic or  as needed (prn)  medications if,  in 
the opi[INVESTIGATOR_122740] -investigator, they pose no additional risk to participant safety or 
assessment  of reactogenicity  and immunogenicity  and do not indicate  a worsening or  treatment  of continued  symptoms 
of medical diagnosis or condition. Herbals, vitamins, and supplements are permitted.  
 
7. Have  an oral temperature  less than 100.0°F.  
 
8. Have  a pulse  [ADDRESS_1145173]  a calculated  body  mass  index  (BMI)  less than or equal  to 35.0 kg/m2 at screening.  
 
12. Screening  laboratories2 in table  below  are within  acceptable  parameters.  
 
[ADDRESS_1145174] Eligibility  Criterion  
BUN  <23 mg/dL  
Serum  creatinine  (female)  <1.3 mg/dL  
Serum  creatinine  (male)  < 1.4 mg/dL  
Alkaline  phosphatase  (female)  <147  U/L 
Alkaline  phosphatase  (male)  <192  U/L 
ALT  (aka SGPT)  <68 U/L 
Total  bilirubin  < 1.3 mg/dL  
Hemoglobin  (female)  >10.9  g/dL 
Hemoglobin  (male)  > 12.4 g/dL 
White  blood  cell count  3000 -12,000  cells/mm3 
Absolute  eosinophil  count  <1201  cells/mm3 
Absolute  neutrophil  count  >1200  cells/mm3 
Platelets  >126,000  cells/mm3 
Hemoglobin  A1C <6.5%  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
32  
  
Urine  for Drugs  of Abuse*  All negative  
HBsAg  Non-reactive  
HCV  antibodies  Negative  
HIV 4th generation  test Negative  
 
*amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cocaine, methadone, opi[INVESTIGATOR_858], oxycodone/oxymorphone, 
phencyclidine  (PCP),  and propoxyphene.  Note  that a prospective  participant  with a positive  urine  for drugs 
of abuse test for a medication reported by [CONTACT_825828] a condition that does not make 
them otherwise ineligible, may be permitted to enroll, at the discretion of the investigator or his designee.  
 
13. Have  no clinically  significant  findings3 on 12-lead electrocardiogram.  
 
3Clinical  significance  will be determined  by a cardiologist.  Examples  of findings  that will lead to exclusion  are significant 
left ventricular hypertrophy, right or left bundle branch block, advanced A -V heart block, non -sinus rhythm (excluding 
isolated premature atrial contractions), pathologic Q wave abnormalities, significant ST -T wave changes, prolonged 
QTc interval.  
 
14. Heterosexually active females of childbearing potential4 must use an acceptable 
contraception method5 from at least [ADDRESS_1145175] until 60 days after the second 
study vaccination.  
 
4Not sterilized  via bilateral  oophorectomy,  salpi[INVESTIGATOR_1656],  hysterectomy,  or successful  Essure® placement  (permanent, 
non-surgical, non -hormonal sterilization) with documented radiological confirmation test at least 90 days after the 
procedure, and still menstruating or <[ADDRESS_1145176] menses, if menopausal.  
 
5Includes full abstinence from sexual intercourse with a male partner, monogamous relationship with vasectomized 
partner  who has been  vasectomized  for 180 days or more or  shown  to be azoospermic  prior  to the participant  receiving 
the study vaccination, barrier methods  such as condoms or  diaphragms/cervical cap, intrauterine devices, NuvaRing®, 
tubal ligation, and licensed hormonal methods such as implants, injectables or oral contraceptives (“the pi[INVESTIGATOR_4382]”).  
 
15. Females  of childbearing  potential  must  have  a negative  serum  pregnancy  test at screening 
and a negative urine pregnancy test within [ADDRESS_1145177]  blood  collected,  stored,  and potentially  used for auto-antibody  studies 
(if a suspected PI[INVESTIGATOR_825785]).  
 
5.1.[ADDRESS_1145178]  not meet  any of the following  exclusion 
criteria:  
DMID  Protocol  17-[ADDRESS_1145179]  the participant  at an 
unacceptable risk of injury, render the participant unable to meet the requirements of the protocol, or may interfere 
with the evaluation of responses or the participant’s successful completion of this trial.  
 
3. Have immunosuppression as a result of an underlying illness or treatment, a recent 
history  or current  use of immunosuppressive  or immunomodulating  disease  therapy8. 
8These include oral or  parenteral (including intra -articular) corticosteroids of any dose within 30 days prior to study 
vaccination,  or high-dose inhaled corticosteroids within 30 days  prior to study vaccination, with high -dose defined as 
per age as using  inhaled high -dose per reference  chart  in the National  Heart,  Lung and  Blood Institute  Guidelines  for 
the Diagnosis  and Management  of Asthma  (EPR -3) or other  lists published  in UPTODATE.  Intranasal  corticosteroids 
are not exclusionary.  Low and moderate potency topi[INVESTIGATOR_167217].  
 
4. Use of anticancer  chemotherapy  or radiation  therapy  (cytotoxic)  within  [ADDRESS_1145180]  known  active  or recently  active  (12 months) neoplastic  disease  or a history  of any 
hematologic malignancy. Non -melanoma treated skin cancers are permitted.  
 
6. Have  known  human  immunodeficiency  virus  (HIV),  chronic  hepatitis  B, or hepatitis  C 
infection.  
 
7. Have  known  hypersensitivity  or allergy  to any components  of the study  vaccines  (AVA, 
CPG adjuvants, aluminum, benzethonium chloride [phemerol], formaldehyde).  
 
8. Have  a history  of receipt or  plan to receive,  while  enrolled  in this study,  a licensed  or 
unlicensed anthrax vaccine (except for the vaccines under study herein).  
 
9. Have  a history  of PI[INVESTIGATOR_106279]9. 
 
9Refer  to Appendix  B: Adverse  Events  of Special Interest  
 
10. Have  a history  of alcohol  or drug abuse  within  [ADDRESS_1145181]  a known  history  of documented  anthrax  disease  or suspected  exposure  to anthrax.  
 
16. Received  immunoglobulin  or other  blood  products,  except  Rho(D)  immunoglobulin, 
within [ADDRESS_1145182] 
study vaccination through 30 days after the second study vaccination.  
 
20. Planning  to donate  blood  within  4 months  following  second  vaccination.  
 
21. Planned  elective  surgery during  study  participation.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
35  
  
22. Member  or immediate  family  member  of the site research  staff found  on the delegation 
log. 
 
23. Previously  served  in the military  any time after 1990  and/or  plan to enlist  in the military 
at any time during the study.  
 
5.1.3 Screen  Failures  
 
A screen  failure  is defined  as a participant  from  whom  informed  consent  is obtained  and 
documented in writing, but who is not subsequently randomized to study treatment.  
Reasons  for screen  failure  are to be recorded  on the electronic  case report  forms  (eCRFs).  
 
All screening procedures must occur [ADDRESS_1145183] for s creening will not be performed more than 
twice (one initial and one repeat test for a total of two times). If the laboratory results are 
abnormal  due to a processing  or handling  error,  the test may be repeated  without  counting 
towards the not -to-exceed total of twice performed.  
 
Participants who are screen failures are permitted to be rescreened one time (only) 
according  to the PI’s discretion.  Otherwise  eligible  prospective  participants  may undergo 
additional rescreening visits in the event that they originally failed screening due to an 
eligibility criterion, such as a laboratory test, that is subsequently amended and does, 
upon amendment, then allow for inclusion. Such rescreening must occur in the time 
period before vaccination as specified in the protocol, and a single repeat of any 
laboratory test, as allowable during the original screening,  is again allowable in this 
situation.  In the event that the participant is rescreened for trial participation, a new 
informed consent form (ICF) must be signed. (This does not apply to those who are 
simply having an abnormal laboratory test repeated to de termine eligibility.) For 
example, if there are any delays between screening and enrollment that cause eligible 
participants to fall outside  the screening window, these  participants may be re -consented 
and rescreened. Participants who complete the rescreening and are randomized in the 
study will not be considered screen failures.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
36  
  
Treatment  Assignment  Procedures  
 
5.2.1 Enrollment  and Randomization  Procedures  
 
Per ICH E6 GCP,  screening  records  will be kept at the  participating  VTEU  site to document  the 
reason why an individual was screened, but failed trial entry criteria. The reasons why 
individuals failed screening will be recorded in the Statistical and Data Coordinating Center’s 
(SDCC) Advantage eClinicalSM (Electronic Data Capture System).  
Once  consented  and upon  entry  of demographic  data and confirmation  of eligibility  for this trial, 
the participant will be enrolled in the electronic data capture system. The participant will be 
enrolled and randomly assigned with equal allocation (1:1) to 1 of 2 treatment groups, stratified 
by [CONTACT_67579] (18 -30 years old and 31 -45 years old) a nd by [CONTACT_547].  
 
Enrollment of participants will be done online using the enrollment module of Advantage 
eClinicalSM. The randomization  code  will be prepared  by [CONTACT_825829]. Advantage eClinicalSM will assign each participant to a 
treatment arm after the demographic and eligibility data have been entered into the system. A 
designated individual at the VTEU site will be provided with a code list for emergency 
unblinding purposes, which will be kept in a secure  place.  
 
Instructions for  use of the enrollment module are included in the Advantage eClinicalSM User’s 
Guide. Manual back -up procedures and instructions are provided for use in the event that the 
participating  VTEU  site temporarily  loses  access  to the internet  or the online  enrollment  system 
is unavailable.  
 
5.2.2 Masking  Procedures  
 
This is a double -blinded  (masked)  clinical  trial. 
 
Participants, site investigators, and study personnel performing any study -related assessments 
following study vaccine administration are blinded to vaccine received. Laboratory personnel 
performing  immunological  assays  will receive  serum  blinded  to participant  ID number,  specimen 
visit number, and allocation group.  
 
The randomization scheme will be generated by [CONTACT_295016]  (i.e., research  pharmacists  performing  study  vaccination  preparations  and unblinded 
study vaccine administrators) at the participating VTEU site.  

DMID  Protocol  17-[ADDRESS_1145184]  for data collection  following  study  vaccine 
administration.  
 
The Safety Monitoring Committee (SMC) may receive data in aggregate and presented by 
[CONTACT_1570]. The SMC may also be provided with expected and observed rates of the 
expected AEs in an unblinded fashion and may request the treatment assignment be unbl inded 
for an individual  participant  if required  for safety  assessment.  The SMC  will review  grouped  and 
unblinded data in the closed session only.  
 
5.2.[ADDRESS_1145185]  Administration  
 
Participants  may voluntarily  withdraw  their consent  for trial participation  at any time and for any 
reason, without penalty or loss of benefits to which they are otherwise entitled.  
 
The site PI [INVESTIGATOR_122747]-investigator  may also withdraw  a participant  from  receiving  the 
study vaccine for any reason.  
 
A participant  may withdraw  or be withdrawn  from  this trial for any of the following reasons:  
 
• Medical disease or condition, or any new clinical finding for which continued 
participation, in the opi[INVESTIGATOR_122740] -investigator, would 
compromise the safety of the participant, or would interfere with the participant’s 
successful  completion  of this trial, or would  interfere  with the evaluation  of responses.  
 
• Participant  withdrawal  of consent  or refusal  to be re-vaccinated.  
 
• Participant  loss to follow -up. 
 
• Termination  of this trial. 
 
• As deemed  necessary  by [CONTACT_7880] [INVESTIGATOR_122747]-investigator  for noncompliance  or 
other reasons.  
 
• New  information  becomes  available  that makes further  participation  unsafe.  
DMID  Protocol  17-[ADDRESS_1145186]  Administration  
 
The primary  reason  for withdrawal  from  this trial will be recorded  on the Study  Status  electronic 
Case Report Form (eCRF). Participants will be encouraged to complete the Early Termination 
Visit. The Early Termination Visit procedures are listed in Section 8.4. 
 
Every attempt will be made to follow all AEs, including solicited injection site and systemic 
reactions,  unsolicited  non-serious  AEs,  SAEs,  MAAEs,  AESIs  (PI[INVESTIGATOR_106279])  ongoing  at the time of 
early withdrawal through resolution as per applicable collection times defined for the specific 
type of AE.  
 
In the case  of participants who fail to appear for a follow -up safety assessment, extensive  effort 
(i.e., three documented contact [CONTACT_825830] a certified  letter)  will be made  to locate  or recall  them,  or at least to determine  their 
health status. These efforts will be documented per site protocol.  
 
The site PI [INVESTIGATOR_122747]-investigator  will inform  the participant  that already  collected  data 
will be retained  and analyzed  even  if the participant withdraws  or is withdrawn  from  this study.  
 
5.2.[ADDRESS_1145187] to follow - 
up after signing the informed consent form (ICF), randomization, and receipt of study vaccine 
may be replaced. If a participant withdraws after signing the ICF, but before randomization 
and/or  receipt  of study  vaccine,  they may also  be replaced. We  do not believe  that it is likely  that 
there will be any such withdrawals, but, should replacement be required, the total number of 
persons enrolled may exceed 40 and approval for the overall number enrolled will be obtained 
from the IRB.  
 
5.2.6 Termination  of Study  
 
Although the sponsor has every intention of completing this trial, it reserves the right to 
terminate this trial at any time for clinical or administrative reasons. Reasons for termination 
include,  but are not limited  to, study  closure  due to SMC  review  and recommendation,  and at the 
discretion of DMID.  
 
If this trial is prematurely terminated  by [CONTACT_456],  any regulatory  authority,  the site PI, or 
appropriate sub-investigator for any reason, the site PI [INVESTIGATOR_29353] -investigator will 
promptly inform the participants and assure appropriate therapy or follow -up for them, as  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
39  
  
necessary.  The site PI [INVESTIGATOR_122747]-investigator  will provide  a detailed  written  explanation 
of the termination to the IRB.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
40  
  
6 STUDY   INTERVENTION/INVESTIGATIONAL   PRODUCT  
 
Study  Product  Description  
 
AV7909  Liquid  Formulation  
 
AV7909 (Emergent BioSystems) is an investigational vaccine that is a preformulated, sterile, 
milky -white suspension (when mixed) for IM injection. It consists of the AVA bulk drug 
substance and CPG 7909 adjuvant. CPG 7909 is a white to off -white lyophilized powder 
manufactured by [CONTACT_825831] (Avecia) in Milford, MA. CPG 7909’s natural 
deoxyribonucleic  acid (DNA)  phosphodiester  backbone  has been  modified  to a phosphorothioate 
backbone, providing the molecule with increased stability and resistance to degradation for 
improved in vivo activity. The  final base  sequence of  the full-length CPG [ADDRESS_1145188] is manufactured at Emergent’s Baltimore, MD facility by 
[CONTACT_825832] 80 and CPG7909 adjuvant to AVA Bulk Drug Substance produced by 
[CONTACT_496081]’s Manufacturing facility at Lansing, MI.  
 
The Thermostable AV7909 Final Drug Product is manufactured by [CONTACT_825833]. The  
vaccine is supplied in a [ADDRESS_1145189] 4432/50 Gray stopper treated with 
FluoroTec® fluorocarbon film and a 20 mm flip -top aluminum seal, stored at 2 -8°C. After 
reconstitution  with 4.0 mL Water  For Injection,  a single  vial contains  approximately  4.8 mL for a 
total of 8 doses per vial (0.5 mL each), with ~1.3 mg/mL aluminum, 0.45 mg/mL CPG7909, 
0.01% formaldehyde, 22.5 ppm benzethonium chloride (phemerol), 0.025% Polysorbate 80, 
0.9% NaCl and 25% trehalose dihydrate at a target pH of 8.0.  
 
Acquisition  
 
Both  vaccine  formulations  will be provided  by [CONTACT_311544].  
 
Diluent  for the lyophilized  formulation  will also be provided  by [CONTACT_825834]. 
Upon request by [CONTACT_122830], both vaccines will be transferred to the following address:  
DMID  Clinical  Materials  Services 
Fisher BioServices  

DMID  Protocol  17-[ADDRESS_1145190] 
Germantown, MD [ZIP_CODE]  
Phone:  [PHONE_6136]  
Fax: [PHONE_6137]  
Email:  [EMAIL_5798]  
 
Study vaccine will be provided through the DMID CMS to the participating VTEU site prior to 
the start of this trial upon  request  and with prior  approval  from  DMID.  Should  the site PI [INVESTIGATOR_825786], further instructions are provided in the protocol -specific MOP.  
 
6.1.1 Formulation,  Storage,  Packaging,  and Labeling  
 
AV7909  Liquid  Formulation  
 
The AV7909 liquid formulation vaccine will be supplied in 6 mL (nominal fill volume) clear 
borosilicate  glass  multi -dose vials  with rubber  stoppers  and flip-top aluminum  seals  for storage. 
A single vial is filled with approximately 6.1 mL. For purposes of this trial, only a single dose 
(0.5 mL) will be used from each vial.  
 
AV7909  liquid  formulation  must  be stored  at 2-8 °C (36-46 °F). Do not freeze.  Do not shake. 
Avoid foaming.  
 
AV7909  Lyophilized  Formulation  
 
AV7909  lyophilized  formulation  must  be stored  between  2-8 °C (36-46 °F).  Do not freeze.  
 
The AV7909 lyophilized product is mixed with the diluent. The diluent is USP grade sterile 
Water  For Injection.  After  reconstitution  with 4.0 mL Water  For Injection,  a single  vial contains 
approximately  4.8 mL. This volume  can allow  for up  to 8 doses  per vial (0.5 mL for  each dose). 
For purposes of this trial, only a single dose (0.5 mL) will be used from each vial. The 
reconstituted product must be used within 24 hours of the time of reconstitution.  If not used 
immediately, the reconstituted vial can be stored at 2 -8°C. 
 
Once the vaccine is pulled into a syringe, if not used immediately, the filled syringe must be 
stored  at 2°C to 8°C (36°F  to 46°F).  Do not freeze.  The storage  time cannot  exceed  24 hours.  
 
Each  of the study  products  will be labeled  according  to manufacturer  specifications  and include 
the statement “Caution: New Drug Limited by [CONTACT_12201].”  
 
Further  details  are included  in the manufacturer’s  Investigator  Brochures  for both vaccines. 
Diluent for the Lyophilized Formulation  
DMID  Protocol  17-[ADDRESS_1145191]  will be provided  via Fisher  BioServices  and stored  at 2°C to 30°C 
(36°F to 86°F).  
 
6.1.[ADDRESS_1145192] be manually recorded daily (excluding non -business 
days and holidays, as applicable) and continuously monitored and recorded during the course of 
this trial per the participating VTEU site standard operating procedu res (SOPs), and 
documentation  will be maintained. If  the temperature  fluctuates  outside  of the required  range,  the 
affected study product(s) must be quarantined at the correct storage temperature and labeled as 
‘Do Not Use’  (until  further  notice).  The participating  VTEU  site’s  research  pharmacist  must  alert 
the site PI [INVESTIGATOR_825787].  In 
the event the temperature fluctuates outside of the required range, including accidental deep - 
freezing or disruption of the cold chain, the affected study product(s) must not be administered. 
The site PI [INVESTIGATOR_825788] e DMID Product Support Team 
at [EMAIL_5255]  for further  instructions  before  any additional  study 
vaccinations are administered. Based on the information collected, DMID and/or the 
manufacturer will determine whether the affected study product(s) can be used. If it cannot be 
used, the site will receive specific instructions on how to return the a ffected study product(s) to 
the DMID CMS or destroy it on site. Additional instructions for quarantine and DMID contact 
[CONTACT_295025] -specific MOP.  
 
Dosage,  Preparation  and Administration  of Study 
Intervention/Investigational Product  
 
See the protocol -specific  MOP  Appendices  for detailed  information  on the preparation,  labeling, 
storage, and administration of study vaccine for each treatment arm. Study vaccine preparation 
will be performed by [CONTACT_825835].  
 
Visually  inspect  the study  product  upon  receipt  and prior  to use. If the study  product(s)  appear(s) 
to have been damaged, contaminated or discolored, contain visible particulate matter or if there 
are any concerns regarding its integrity, do NOT use the affected study product(s). The affected 
study product(s) must be quarantined as per storage requirements and labeled as ‘Do Not Use’ 
(until further notice). The site principal investigator [INVESTIGATOR_825789] [EMAIL_5255]  and 
DMID  Clinical  Project  Manager  for further  instructions  before  any additional  study  vaccinations 
are administered. Based on the information collected, DMID and/or the manufacturer will  

DMID  Protocol  17-[ADDRESS_1145193](s) can be used. If it cannot be used, the site will 
receive  specific  instructions  on how to return  the affected  study  product(s)  to the DMID  CMS  or 
destroy  it on site. If the study  product  is unusable, study  personnel  will use another  vial from  the 
study supply. Replacement vials may be  requested by [CONTACT_295023]. Additional instructions 
for quarantine and DMID contact [CONTACT_295025] -specific MOP.  
 
Study vaccine administration to the participant will be performed by [CONTACT_825836] -related assessments or have p articipant contact [CONTACT_825837]. One dose of study vaccine will be 
administered to the participant via a single IM injection into the deltoid muscle of the 
participant’s preferred arm on the day of study vaccin e administration. See the protocol -specific 
MOP  for information  on how to administer  IM injections.  The site of injection  (right  or left arm) 
and time of study vaccine administration will be recorded on the appropriate eCRF. The second 
study vaccination will be given in the opposite arm.  
 
Preparation  of the product  will be performed as  specified  in detail  in the protocol -specific  MOP.  
 
Accountability  Procedures  for the Study  Intervention/Investigational 
Product  
 
After receipt of the study vaccine(s), the site PI [INVESTIGATOR_825790]. The site PI [INVESTIGATOR_825791] t he participating VTEU site research 
pharmacist who will be responsible for maintaining complete records and documentation of  
study product receipt, accountability, dispensation, storage conditions, and final disposition of  
the study product(s). Study produ ct accountability records and dispensing logs will also capture 
the date of study vaccine preparation/administration, time of study vaccine preparation, 
expi[INVESTIGATOR_825792],  time study  vaccine  is drawn  into the syringe,  and amount 
of study vaccine withdrawn for administration. Time of study vaccine administration will be 
recorded on the appropriate eCRF. All study product(s), whether administered or not, must be 
documented on the appropriate study product accountability recor d or dispensing  log. The 
sponsor’s monitoring staff will verify the participating VTEU site study product accountability 
records and dispensing logs per the site monitoring plan. After a single dose is withdrawn from 
an AV7909 formulation vial (liquid or reconstituted ly ophilized) for administration to a 
participant, the vial and any unused contents will thereafter be maintained at room temperature 
pending final drug accountability procedures.  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
44  
  
Assessment  of Participant  Compliance  with  Study 
Intervention/Investigational Product  
 
Study vaccine will be administered to the participant by [CONTACT_825838]’s  randomized  treatment 
assignment and as described in Section 6.2. Study vaccine administration and any 
noncompliance with the dose schedule will be recorded on the appropriate eCRF.  
 
Concomitant  Medications/Treatments  
 
Administration of any medications, therapi[INVESTIGATOR_014], or vaccines will be recorded on the appropriate 
eCRF. Concomitant medications will include all current medications and medications taken in 
the [ADDRESS_1145194]. Concomitant medications (new medications or changes to previously 
reported  medications)  that are reported  after Day 64 will only be recorded when  they are taken  in 
relation to an MAAE, AESI (PI[INVESTIGATOR_106286]), or SAE. Prescription and over -the-counter drugs will be 
included as well as herbals, vitamins, and supplements. Use of a new medication should prompt 
evaluation for the occurrence of any AE, MAAE, AESI (PI[INVESTIGATOR_106286]), or SAE.  
 
Medications that might interfere with the evaluation of the investigational product(s) should not 
be used during the trial -reporting period (approximately 12 months after the second study 
vaccination,  approximately  Day 380) unless  clinically  indicated  as part of the participant’s  health 
care. Medications in this category include the prohibited medications per the Participant 
Exclusion  Criteria  (see Section  5.1.2 ). In addition,  the site PI [INVESTIGATOR_122747]-investigator  may 
identify other medications, herbals, vitamins, or supplements that should not be used due to a  
risk to participant safety or assessment of reactogenicity and immunogenicity.  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
45  
  
7 STUDY  PROCEDURES/EVALUATIONS  
 
Clinical  Evaluations  
 
A complete medical history will be obtained by [CONTACT_825839]. 
Participants  will be queried  regarding  a history  of significant  medical  disorders  of the head,  eyes, 
ears, nose, throat, cardiovascular system, lungs, gastrointestinal tract, liver, pancreas, kidney, 
urologic system, nervous system, blood, lymph nodes, endocrine system, musculoskeletal 
system, skin, and genital/reproductive tract. A history of any allergies, cancer, immune 
deficiency, psychiatric illness, substance abuse, autoimmune disease, and any other significant 
medical history will be solicited. At all subsequent visits, an interim medical history will be 
obtained  by [CONTACT_825840], when within the respective reporting period. The interim medical history will 
include an assessment for new medical conditions, MAAEs, and symptoms suggestive of AESIs 
(PI[INVESTIGATOR_106279]).  
 
Concomitant  medications  will be collected  as described  in Section  6.5. 
 
At the screening visit, a physical examination will be performed on all participants, by a study 
clinician licensed to make medical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_119251]-investigator, to include the following organs and organ systems: abdomen, 
cardiovascular/heart, extremities, general appearance, HEENT, hepatobiliary/spleen, lymph 
nodes, musculoskeletal, neck, neurological, pulmonary/chest, and skin. Specific attention will be 
placed  in assessing  for physical  signs  of PI[INVESTIGATOR_106279].  At the vaccination  visit and at follow -up visits 
after each study vaccination, a targeted physical examination may be performed by a study 
clinician licensed to make med ical diagnoses and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_119251]-investigator, if indicated, based on the participant’s interim medical history. Targeted 
physical examinations should also include an assessment for signs suggestive of PI[INVESTIGATOR_106279].  
 
Height and weight will be collected at the screening visit for calculation of the BMI. Vital signs 
(oral temperature, pulse, and blood pressure) will be collected at the screening visit and prior to 
each study vaccination. Vital signs assessed on Day [ADDRESS_1145195].  
 
Reactogenicity  assessments  will include  an assessment  of solicited  AEs occurring  for the week 
after each study vaccination (Days 1 through 8 and target of Days 15 through 22, inclusive), 
which includes an assessment of injection site reactions including pruritus, ecchymosis,  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
46  
  
erythema,  edema/induration,  pain,  and tenderness  as well as systemic  reactions  including  fever, 
feverishness, fatigue, malaise, myalgia (exclusive of the injection site muscle pain), arthralgia, 
headache, and nausea. If a reactogenicity event persists on Day 8 or 22 (or the last day of the 
second reactogenicity period, should the second vaccin ation occur after Day 15), it will be 
followed until resolution. Pre -administration reactogenicity assessments will be performed 
immediately prior to each study vaccin ation to establish baseline.  
 
Participants will be observed in the clinic for at least [ADDRESS_1145196]-administration  reactogenicity  assessments  will 
be performed, and any AE/SAEs will be recorded on the appropriate eCRF prior to discharge 
from the clinic. The study vaccination site will also be examined on approximately Day [ADDRESS_1145197] vaccination and Day 22 after the second (or the last day  of the second reactogenicity 
period, should the second vaccinatio n occur after Day 15).  
 
All participants  will complete  a memory  aid using  an eMemory  Aid from  the time of first study 
vaccination through Day 8 and the second vaccination through Day 22 (or the last day of the 
second reactogenicity period, should the second vaccination occur after Day 15). Memory aids 
will be completed online and reviewed by [CONTACT_5984].  
 
Laboratory  Evaluations  
 
Clinical  laboratory  evaluations  and special  assays  are described  below.  Refer  also to Sections  4 
and 8 as well as Appendix A : Schedule of Study Procedures and Evaluations and Appendix B : 
Adverse Events of Special Interest.  
 
7.2.[ADDRESS_1145198] (β hCG) will be sent with the screening laboratory specimens and a 
point -of-care urine pregnancy test will be performed on Days 1 and 15 (or the day of second 
vaccination should the second vaccination occur after Day 15), with result s determined to be 
negative  before  randomization  and vaccination  for all females  of childbearing  potential.  Results 
must be negative and known prior to randomization on Day 1 and administration of vaccine on 
Day 15 (or the day of second vaccination should the second vaccination occur after Day 15) to 
be eligible for participation in this trial and receipt of study vaccinations.  
 
Clinical safety laboratory parameters will be collected at the screening study visit. The results 
from the clinical safety laboratory parameters collected at the screening visit will be reviewed 
prior  to the first study vaccination and will be  within acceptable ranges to be  eligible  for receipt 
of the first study  vaccination.  The safety  laboratories  will be repeated  on approximately  Day 29. 

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
47  
  
 
At screening,  tests for HIV infection  (fourth  generation  antigen -antibody  test),  acute  and chronic 
hepatitis  B infection  (HBsAg),  and hepatitis  C infection  (antibody)  will be collected  and must  be 
negative for a participant to be deemed eligible. In addition, HgbA 1C will be performed at 
screening and the value must fall within the protocol -specified eligibility range in order for 
prospective  participants  to join the study.  A urine  study  for drugs  of abuse  must  also be negative 
for prospective participants to be deemed eligible. Participants will be encouraged to review 
results, when abnormal, with their primary care physicians. These tests will not be routinely 
retested during the trial.  
 
Test Eligibility  Criterion  
BUN  <23 mg/dL  
Serum  creatinine  (female)  <1.3 mg/dL  
Serum  creatinine  (male)  < 1.4 mg/dL  
Alkaline  phosphatase  (female)  <147  U/L 
Alkaline  phosphatase  (male)  <192  U/L 
ALT  (aka SGPT)  <68 U/L 
Total  bilirubin  < 1.3 mg/dL  
Hemoglobin  (female)  >10.9  g/dL 
Hemoglobin  (male)  > 12.4 g/dL 
White  blood  cell count  3000 -12,000  cells/mm3 
Absolute  eosinophil  count  <1201  cells/mm3 
Absolute  neutrophil  count  >1200  cells/mm3 
Platelets  >126,000  cells/mm3 
Hemoglobin  A1C <6.5%  
Urine  for Drugs  of Abuse*  All negative  
HBsAg  Non-reactive  
HCV  antibodies  Negative  
HIV 4th generation  test Negative  
 
*amphetamines,  barbiturates,  benzodiazepi[INVESTIGATOR_1651],  cocaine,  methadone,  opi[INVESTIGATOR_858],  oxycodone/oxymorphone, 
phencyclidine (PCP), and propoxyphene. Note that a prospective participant with a positive urine for drugs of 
abuse test for a medication reported by [CONTACT_825828] a condition that does not make them 
otherwise ineligible, may be permitted to enroll, at the discretion of the investigator or his designee.  
 
 
 
The volume  of venous blood  to be collected for  laboratory  evaluations is presented  in Table  3. 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
48  
  
7.2.2 Special  Assays  or Procedures  
 
Serological/Immunogenicity  Assays  
 
Serum will be collected for toxin neutralization assay (TNA) and reported as ED 50 and NF 50 and 
collected for anti -PA IgG concentration by [CONTACT_825841] µg/mL. Blood samples (sera) 
for determination of TNA titers and anti -PA IgG will be collected on the days outlined in the 
Schedule  of Events  in Appendix  A. Specific  procedures  related  to collection,  processing,  storage, 
and shipment of the samples are provided in the Manual of Procedures.  
 
The TNA assay being used in this trial has been validated by [CONTACT_257690] 
(Columbus,  Ohio)  under  National  Institute  of Allergy  and Infectious  Diseases  sponsorship  
{Clement, 2008}. The assay measures the functional ability of antisera containing anti -PA 
antibodies  to specifically  protect  cells against  B. anthracis  lethal  toxin  cytotoxicity  {Stinson  et 
al, 2005; Li et al., 2008}. The TNA assay results will be reported as the reciprocal of a serum 
sample dilution that results in 50% neutralization of lethal toxin cytotoxicity (50% effective 
dilution; ED 50). To standardize assay results, the results are divided by [CONTACT_257691] [ADDRESS_1145199], and the resulting ratio is reported as a 50% neutralization factor, NF 50. 
Reference  standard  AVR801  will be used.  
 
The method of quantitative anti -PA IgG ELISA has been described previously (Semenova VA, 
Schiffer  J, Steward -Clark  E, Soroka  S, Schmidt  DS, Brawner  MM,  Lyde  F, Thompson  R, Brown 
N, Foster L, Fox S, Patel N, Freeman AE, Quinn CP J Immunol Methods. 2012 Feb 28; 376(1 - 
2):97 -107).  
 
 
 
 
 
 
 
 
 
Table  3: Venipuncture  Volumes  
 
 
 
Visit  Number   
 
0  
 
1  
 
2  
 
3  
 
4  
 
5  
 
6  
 
7  
 
8  
Cumulative Blood 
Volume  Total  (mL)  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
49  
  
 
 
Day#  
Screening 
D-28 to -2  
 
1  
 
8  
 
15  
 
22  
 
29  
 
64  
 
195  
 
380  
Vaccination   X  X       
Serum  
pregnancy  for 
women   
6          
6 
Hematology  6     6    12 
Chemistry  6     6    12 
Hgb A1C 6         6 
HIV,  hepatitis 
B, hepatitis  C 12         12 
Stored  Serum*  10         10 
Serological 
Assays  (TNA 
and anti -PA 
IgG)   
20†  
20  
20†  
20  
20  
20  
20  
20  
160 
Per Visit 
Blood  Volume 
Total (mL)   
46  
20  
20  
20  
20  
32  
20  
20  
20  
Running 
Blood  Volume 
Total (mL)   
46  
72  
92  
112  
132  
164  
184  
204  
224  
218 
# Note  that Day 15, the visit at which  the participant  receives  the second  vaccination,  has an acceptable  window  of 
Days 15 through 18, inclusive. Should the targeted Day 15 visit occur after Day 15, the subsequent dates are 
adjusted to keep the same intervals as in the Table above.  
* This blood is  drawn to  store  serum that could be  used in the event  of a post -vaccination  PI[INVESTIGATOR_106286]. For participants 
who agree  to secondary  use, the serum  may be used for other secondary  use purposes;  for those  who do  not agree 
to secondary use, the serum will be discarded when required after study completion.  
† Blood  must  be drawn  prior  to each study  vaccination.  
 
7.2.3 Specimen  Preparation,  Handling,  and Shippi[INVESTIGATOR_007]  
 
[IP_ADDRESS]  Instructions  for Specimen  Preparation,  Handling,  and Storage  
 
Instructions  for specimen  preparation,  handling,  and storage  are included  in the Central  Clinical 
Laboratory Manual and protocol -specific MOP as appropriate.  
 
[IP_ADDRESS]  Specimen  Shipment  
 
Specimen  shipment  will occur  at intervals  during  the course  of this trial following  all applicable 
International Air Transport Association (IATA) requirements and according to the specifics for 
storage temperature and documentation as detailed in the Central Clinical Laboratory Manual 
and protocol -specific MOP, as appropriate.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
50  
  
 
Specimens  for clinical  safety  laboratory  evaluations  will be shipped  from  the participating  VTEU 
site to the commercial laboratory except those done locally.  
 
Specimens  for TNA  and ELISA  will be shipped  from  the participating  VTEU  as outlined  in the 
MOP.  
 
Further  instructions  for specimen  shipment  are included  in the protocol -specific  MOP,  as 
appropriate.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
51  
  
8 STUDY  SCHEDULE  
 
Complete study schedule details listed by [CONTACT_19807]. Refer also to 
Sections  4 and 7 as well as Appendix  A: Schedule  of Study  Procedures  and Evaluations  and 
Appendix B : Adverse Events of Special Interest.  
 
Screening  and Enrollment  Visits  
 
During recruitment, the  prospective participant may provide to research team members personal 
information by [CONTACT_825842]. This information may be used for screening and 
determining  eligibility.  The IRB will approve  all methods  of screening  and recruiting  along  with 
any required documents or scripts, if used.  
 
8.1.1 Visit  0, Screening  (Day -28 to -2), Clinic  Visit  
 
• Participants will be provided with a description of this trial (purpose and study 
procedures)  and asked  to read and sign the ICF.  The ICF will be signed  prior  to 
performing any study procedures.  
 
• Demographic  information  will be obtained  by [CONTACT_825843].  
 
• Eligibility  criteria  will be reviewed with  participants  to ensure  eligibility.  
 
• Complete  medical  history  will be obtained  by [CONTACT_825844].  
 
• All concomitant medications taken within 60 days prior to signing the ICF will be 
reviewed  with participants  and recorded  to determine  stability  of chronic  diseases  and 
eligibility.  
 
• Vital signs (oral temperature, pulse, and BP) will be obtained to ensure eligibility. 
Participants  must  not eat or drink  anything  hot or cold,  or smoke  within  10 minutes  prior 
to taking oral temperature.  
 
• Height  and weight  will be measured  and recorded  for the calculation  of BMI.  
 
• A physical examination will be performed on all participants to include the following 
organs and organ systems: abdomen, cardiovascular/heart, extremities, general 
appearance, HEENT, hepatobiliary/spleen, lymph nodes, musculoskeletal, neck, 
neurological,  pulmonary/chest,  and skin.  Specific  attention  will be  placed  in assessing  for 

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
52  
  
physical signs of PI[INVESTIGATOR_106279]. The examination will be performed by a study clinician 
licensed  to make  medical  diagnoses  and listed  on the Form  FDA  1572  as the site PI  [INVESTIGATOR_119251]-investigator.  
 
• A serum pregnancy test will be performed for all females of childbearing potential. 
Results must be negative to ensure eligibility. Women of childbearing potential will be 
counseled  to avoid  pregnancy  until 60 days after the second  (final)  vaccination,  i.e., Day 
75. 
 
• Venous  blood  and urine  will be collected  for the tests outlined  in Sections  7.2.[ADDRESS_1145200] be within the acceptable range as outlined in the eligibility criteria to be 
eligible for randomization and vaccination.  
 
• A 12-lead electrocardiogram  will be performed  and reviewed  by [CONTACT_825845].  
 
8.1.2 Visit  1, Day 1, Enrollment  (Vaccination),  Clinic  Visit  
 
• Participant’s  willingness  to participate  will be reconfirmed  and documented  in the study 
records prior to performing any further study procedures, including administration of 
study vaccination.  
 
• Eligibility  criteria,  including  results  from  screening  lab tests,  will be reviewed  with 
participants prior to the first study vaccination to ensure continued eligibility.  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions,  stability  of 
chronic  diseases  and symptoms  suggestive  of PI[INVESTIGATOR_106279],  will be obtained by  [CONTACT_825846]. Any changes in medical history since the 
screening visit will be reviewed with participants prior to study vaccination to ensure 
continued eligibility.  
 
• All concomitant  medications  will be reviewed  with participants  prior  to study  vaccination 
for accuracy and completeness. Any new concomitant medications taken since the 
screening visit will be reviewed with participants prior to study vaccination to ensure 
continued eligibility. Medications reported in the eCRF are limited to those taken within 
[ADDRESS_1145201] study vaccination.  
 
• Vital signs (oral temperature, pulse, and BP) will be obtained prior to study vaccination 
to ensure continued eligibility. Vital signs assessed on Day [ADDRESS_1145202]  not eat or drink  anything  hot or cold,  or 
smoke within 10 minutes prior to taking oral temperature.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
53  
  
• A targeted physical examination, including an assessment for signs suggestive of 
PI[INVESTIGATOR_106279],  may be performed,  by a study  clinician licensed  to make  medical  diagnoses 
and listed on the Form FDA 1572 as the site PI [INVESTIGATOR_11637] -investigator, prior to study 
vaccination,  if indicated  based  on review  of complete  medical  history  and any updates 
obtained by [CONTACT_825847]. If not indicated, no 
physical examination is necessary.  
 
• A urine  pregnancy  test will be performed  locally  by [CONTACT_11255]  [ADDRESS_1145203]  be negative  and known 
prior to randomization and study vaccination. Women of childbearing potential will be 
counseled to avoid pregnancy until 60 days after the second (final) vaccination, i.e., Day 
75. 
 
• Venous  blood  will be collected  prior  to study  vaccination  for baseline  serological  assays 
(TNA and anti -PA ELISA).  
 
• Participants  will be randomized  in Advantage  eClinicalSM and randomly  assigned  to a 
treatment arm prior to study vaccination.  
 
• Pre-administration  reactogenicity  assessments  will be performed  immediately  prior  to 
study vaccination to establish baseline.  
 
• Participants  will then receive  one dose of study  vaccine  via a single  IM injection  into the 
deltoid muscle of the participant’s preferred arm. The site of injection (right or left arm) 
and time of study vaccine administration will be recorded on the appropriate eCRF. 
Participants will be observed in the clinic for at least [ADDRESS_1145204] -administration reactogenicity 
assessments will be performed, and any AE/SAEs will be recorded on the appropriate 
eCRF prior to discharge from the clinic.  
 
• Participants will be trained to complete a web based “eMemory Aid” and are expected to 
enter  information  in the eMemory  Aid each day. Participants  using  the eMemory  Aid will 
also be provided a paper memory aid for their use in the event they are unable to access 
the web -based system. The participants will be asked to enter the information from the 
paper memory aid into the eMemory Aid once they are able to access the web -based 
system.  Participants will be provided with instructions on completion of the elec tronic 
memory aid and other study -related materials. They will learn to record daily oral 
temperature, solicited injection site and systemic reactions, unsolicited AEs, and 
concomitant medications. Participants will be encouraged to take their oral tempera ture 
around the same time each day. They must not eat or drink anything hot or cold, or  
smoke within [ADDRESS_1145205] AEs  prior  to 
discharge from the clinic. They will be instructed to notify the study center if they 
develop any severe reactions after study vaccination. If the site PI [INVESTIGATOR_29353] - 
investigator deems the reaction severe enough, further instructions will be given to the 
participant  on the proper  course  of action,  including  a return  to the clinic  for immediate 
evaluation if appropriate.  
 
Follow -up Visits  
 
Follow -up visits  are scheduled  in reference  to the study  vaccination  date as indicated  for each 
visit window.  
 
8.2.1 Visit  2, Day 8, Clinic  Visit  (End  of Solicited  Reactogenicity  Period after  First 
Vaccination)  
(Window:  Day 8 to Day 11,  inclusive)  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions,  stability  of 
chronic diseases and symptoms suggestive of AESIs (PI[INVESTIGATOR_106279]), will be obtained by 
[CONTACT_825848].  
 
• All changes  to concomitant  medications  will be recorded on  the appropriate  eCRF.  
 
• All MAAEs  and AE/SAEs  will be recorded  on the appropriate  eCRF.  
 
• eMemory  Aid information  will be reviewed  with participants.  If any reactogenicity 
events are on -going, they will be recorded as AEs.  
 
• A targeted  physical  examination,  including  an assessment  for signs  suggestive  of AESIs 
(PI[INVESTIGATOR_106279]), may be performed, if indicated based on review of interim medical history, 
by a study clinician licensed to make medical diagnoses and listed on the Form FDA 
1572 as the site PI [INVESTIGATOR_11637] -investigator.  
 
• The study  vaccination  site will be examined.  
 
• Venous  blood  will be collected  for serological  assays  (TNA  and anti-PA ELISA).  
 
• Women  of childbearing  potential  will be counseled  to avoid  pregnancy  until 60 days after 
the second (final) vaccination, i.e., Day 75.  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
55  
  
8.2.2 Visit  3, Day 15, Clinic  Visit  (Second  Vaccination) 
(Window: Day 15 to 18, inclusive)  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions,  stability  of 
chronic diseases and symptoms suggestive of AESIs (PI[INVESTIGATOR_106279]), will be obtained by 
[CONTACT_825848].  
 
• All changes  to concomitant  medications will  be recorded  on the appropriate  eCRF.  
 
• All MAAEs  and AE/SAEs  will be recorded  on the appropriate  eCRF.  
 
• A targeted  physical  examination,  including  an assessment  for signs  suggestive  of AESIs 
(PI[INVESTIGATOR_106279]), may be performed, if indicated based on review of interim medical history, 
by a study clinician licensed to make medical diagnoses and listed on the Form FDA 
1572 as the site PI [INVESTIGATOR_11637] -investigator.  
 
• Venous  blood  will be collected  for serological  assays  (TNA  and anti-PA ELISA).  
 
• Criteria for receipt of the second vaccination will be reviewed with participants prior to 
the second  study  vaccination  to ensure  continued  eligibility.  These  criteria  are identical  to 
the eligibility criteria, with the following exceptions: continued consent must be 
confirmed, age will not be re -confirmed, physical exam will not be required to determine 
good health, BMI will not be recalculated, screening labs will not be repeated, a nd 
screening electrocardiogram will not be repeated.  
 
• Vital signs (oral temperature, pulse, and BP) will be obtained prior to study vaccination 
to ensure continued eligibility. Vital signs assessed on Day [ADDRESS_1145206]  not eat or drink  anything  hot or cold,  or 
smoke within 10 minutes prior to taking oral temperature.  
 
• A urine  pregnancy  test will be performed  locally  by [CONTACT_11255]  [ADDRESS_1145207]  be negative  and known 
prior to study vaccination. Women of childbearing potential will be counseled to avoid 
pregnancy until 60 days after the second (final) vaccination, i.e., Day 75.  
 
• Pre-administration  reactogenicity  assessments  will be performed  immediately  prior  to 
study vaccination to establish baseline.  
 
• Participants  will then receive  their second  dose of study  vaccine  via a single  IM injection 
into the deltoid muscle of the opposite arm of the first vaccination. The site of injection 
(right or left arm) and time of study vaccine administration will be recorded on the  
DMID  Protocol  17-[ADDRESS_1145208] -administration 
reactogenicity  assessments  will be performed,  and any AE/SAEs  will be recorded  on the 
appropriate eCRF prior to discharge from the clinic.  
 
• Participants  will be re-trained  to complete  a web based eMemory  Aid and are expected  to 
enter  information  in the eMemory  Aid each day. Participants  using  the eMemory  Aid will 
also be provided a paper memory aid for their use in the event they are unable to access 
the web -based system. The participants will be asked to enter the information from the 
paper memory aid into the eMemory Aid once they are able to access the web -based 
system. Participants will be reminded to record daily oral temperature, solicited injection 
site and systemic reactions, unsolicited AEs, and concomitant medications. Participants 
will be encou raged to take their oral temperature around the same time each day. They 
must not eat or drink anything hot or cold, or smoke within [ADDRESS_1145209] AEs 
prior t o discharge from the clinic. They will be instructed to notify the study center if  
they develop any severe reactions after study vaccination. If the site PI [INVESTIGATOR_825793]-investigator  deems  the reaction  severe  enough,  further  instructions  will be given  to 
the participant on the proper course of action, including a return to the clinic for 
immediate evaluation if appropriate.  
 
• Note  that all subsequent  visits  are based  on the day that Visit  [ADDRESS_1145210] the schedule assuming that Visit  3 occurs on  
Day 15.  
 
8.2.3 Visit  4, Day 22, Clinic  Visit  (End  of Solicited  Reactogenicity  Period  after  Second 
Vaccination)  
(Window:  Day 22 to 25, inclusive)  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions,  stability  of 
chronic diseases and symptoms suggestive of AESIs (PI[INVESTIGATOR_106279]), will be obtained by 
[CONTACT_825848].  
 
• All changes  to concomitant  medications  will be recorded on  the appropriate  eCRF.  
 
• All MAAEs  and AE/SAEs  will be recorded  on the appropriate  eCRF.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
57  
  
• eMemory  Aid information  will be reviewed  with participants.  If any reactogenicity 
events are on -going, they will be recorded as AEs.  
 
• A targeted  physical  examination,  including  an assessment  for signs  suggestive  of AESIs 
(PI[INVESTIGATOR_106279]), may be performed, if indicated based on review of interim medical history, 
by a study clinician licensed to make medical diagnoses and listed on the Form FDA 
1572 as the site PI [INVESTIGATOR_11637] -investigator.  
 
• The study  vaccination  site will be examined.  
 
• Venous  blood  will be collected  for serological  assays  (TNA  and anti-PA ELISA).  
 
• Women  of childbearing  potential  will be counseled  to avoid  pregnancy  until 60 days after 
the second (final) vaccination – Day 75.  
 
8.2.4 Visit 5, Day 29, Clinic Visit 
(Window:  Day 27 to 31, inclusive)  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions,  stability  of 
chronic diseases and symptoms suggestive of AESIs (PI[INVESTIGATOR_106279]), will be obtained by 
[CONTACT_825848].  
 
• All changes  to concomitant  medications  will be recorded on  the appropriate  eCRF.  
 
• All MAAEs  and AE/SAEs  will be recorded  on the appropriate  eCRF.  
 
• A targeted  physical  examination,  including  an assessment  for signs  suggestive  of AESIs 
(PI[INVESTIGATOR_106279]), may be performed, if indicated based on review of interim medical history, 
by a study clinician licensed to make medical diagnoses and listed on the Form FDA 
1572 as the site PI [INVESTIGATOR_11637] -investigator.  
 
• Venous  blood  will be collected  for serological  assays  (TNA  and anti-PA ELISA).  
 
• Venous  bloodwill  be collected  for standard  clinical  safety  evaluations  (tests  outlined  in 
Table 10).  
 
• Women  of childbearing  potential  will be counseled  to avoid  pregnancy  until 60 days after 
the second (final) vaccination, i.e., Day 75.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
58  
  
8.2.5 Visit 6, Day 64, Clinic Visit 
(Window:  Day 60-68, inclusive)  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions,  stability  of 
chronic diseases and symptoms suggestive of AESIs (PI[INVESTIGATOR_106279]), will be obtained by 
[CONTACT_825848].  
 
• All changes  to concomitant  medications  will be recorded on  the appropriate  eCRF.  
 
• All MAAEs  and AE/SAEs  will be recorded  on the appropriate  eCRF.  
 
• A targeted  physical  examination,  including  an assessment  for signs  suggestive  of AESIs 
(PI[INVESTIGATOR_106279]), may be performed, if indicated based on review of interim medical history, 
by a study clinician licensed to make medical diagnoses and listed on the Form FDA 
1572 as the site PI [INVESTIGATOR_11637] -investigator.  
 
• Venous  blood  will be collected  for serological  assays  (TNA and  anti-PA ELISA).  
 
• Women  of childbearing  potential  will be counseled  to avoid  pregnancy  until 60 days after 
the second (final) vaccination, i.e., Day 75.  
 
8.2.6 Visit 7, Day 195, Clinic Visit 
(Window:  Day 188 to 202, inclusive)  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions,  stability  of 
chronic diseases and symptoms suggestive of AESIs (PI[INVESTIGATOR_106279]), will be obtained by 
[CONTACT_825848]  
 
• All changes  to concomitant  medications  will be recorded  on the appropriate  eCRF  only if 
they occurred after Day 64 and in relation to an MAAE, SAE, or AESI (PI[INVESTIGATOR_106286]).  
 
• MAAEs,  SAEs,  and AESIs  (PI[INVESTIGATOR_106279])  will be recorded  on the appropriate eCRF.  
 
• A targeted  physical  examination,  including  an assessment  for signs  suggestive  of AESIs 
(PI[INVESTIGATOR_106279]), may be performed, if indicated based on review of interim medical history, 
by a study clinician licensed to make medical diagnoses and listed on the Form FDA 
1572 as the site PI [INVESTIGATOR_11637] -investigator.  
 
• Venous  blood  will be collected  for serological  assays  (TNA and  anti-PA ELISA).  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
59  
  
Final  Visit  
 
8.3.1  Visit 8, Day 380, Clinic Visit 
(Window:  Day 373 to 387, inclusive)  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions,  stability  of 
chronic diseases and symptoms suggestive of AESIs (PI[INVESTIGATOR_106279]) will be obtained by 
[CONTACT_825848].  
 
• All changes  to concomitant  medications  will be recorded  on the appropriate  eCRF  only if 
they occurred after Day 64 and in relation to an MAAE, SAE, or AESI (PI[INVESTIGATOR_106286]).  
 
• MAAEs,  SAEs,  and AESIs  (PI[INVESTIGATOR_106279])  will be recorded  on the appropriate  eCRF.  
 
• A targeted physical examination, including an assessment for signs suggestive of AESIs 
(PI[INVESTIGATOR_106279])  may be performed,  if indicated  based  on review  of interim  medical  history, by 
a study  clinician  licensed  to make  medical  diagnoses  and listed  on the Form  FDA  1572  as 
the site PI [INVESTIGATOR_11637] -investigator.  
 
• Venous  blood  will be collected  for serological  assays  (TNA and  anti-PA ELISA).  
 
Early  Termination  Visit  (if needed)  
 
The following  activities  will be performed  at the Early  Termination  Visit  on participants  who 
withdraw, or are withdrawn or terminated from this trial:  
 
• Interim  medical  history,  including  an assessment  for new medical  conditions,  stability  of 
chronic diseases and symptoms suggestive of AESIs (PI[INVESTIGATOR_106279]), will be obtained by 
[CONTACT_825848].  
 
• All changes  to concomitant  medications  will be recorded  on the appropriate  eCRF  if 
within the window.  
 
• All MAAEs  and AE/SAEs  will be recorded  on the appropriate  eCRF,  if within  the 
windows.  
 
• eMemory  Aid information  will be reviewed  with participants,  if not previously  completed 
and reviewed.  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
60  
  
• Vital  signs  (oral  temperature,  pulse,  and BP) may be obtained  if indicated.  Participants 
must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking 
oral temperature.  
 
• A targeted physical examination, including an assessment for signs suggestive of AESIs 
(PI[INVESTIGATOR_106279])  may be performed,  if indicated  based  on review  of interim  medical  history, by 
a study  clinician  licensed  to make  medical  diagnoses  and listed  on the Form  FDA  1572  as 
the site PI [INVESTIGATOR_11637] -investigator.  
 
• The study  vaccination  site will be examined,  if the early  termination  falls from  Days  1 to 
8 after either study vaccination.  
 
• Post-administration  reactogenicity  assessment  will be performed,  if the early  termination 
falls from Days 1 to 8 after either study vaccination.  
 
• Venous  blood  will be collected  for clinical  safety  labs and auto-antibodies,  if not 
previously drawn.  
 
• Venous  blood  will be collected  for serological  assay  (TNA  and anti-PA ELISA).  
 
Unscheduled  Visit  (if needed)  
 
An Unscheduled  Visit  may occur  at any time during  this trial. Any of the following  activities 
may be performed:  
 
• Interim medical history, including an assessment for new medical conditions, stability of 
chronic diseases and symptoms suggestive of AESIs (PI[INVESTIGATOR_106279]) will be obtained by 
[CONTACT_825849] (if indicated).  
 
• All changes  to concomitant  medications  will be recorded  on the appropriate  eCRF,  if 
within the window.  
 
• All MAAEs  and AE/SAEs  will be recorded  on the appropriate  eCRF,  if within  the 
windows.  
 
• eMemory  Aid information  will be reviewed  with participants,  if applicable.  
 
• Vital  signs  (oral  temperature,  pulse,  and BP) may be obtained  if indicated.  Participants 
must not eat or drink anything hot or cold, or smoke within 10 minutes prior to taking 
oral temperature.  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
61  
  
• A targeted  physical  examination,  including  an assessment  for signs  suggestive  of AESIs 
(PI[INVESTIGATOR_106279]), may be performed, if indicated based on review of interim medical history, 
by a study clinician licensed to make medical diagnoses and listed on the Form FDA 
1572 as the site PI [INVESTIGATOR_11637] -investigator.  
 
• The study  vaccination  site will be examined,  if the unscheduled  visit falls from  Days  1 to 
8 after either study vaccination.  
 
• Post-administration  reactogenicity  assessment  will be performed,  if the unscheduled  visit 
falls from Days 1 to 8 after either study vaccination.  
 
• Venous  blood  will be collected  for clinical  safety  labs and serological  testing  (TNA  and 
anti-PA ELISA), if not already performed.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
62  
  
9 ASSESSMENT  OF SAFETY  
 
Specification  of Safety  Parameters  
 
Safety  will be assessed  by [CONTACT_825850]:  
 
1. SAEs  occurring  from  the time of the first study  vaccination  through  approximately  12 
months after the second study vaccination (approximately Day 380).  
 
2. Solicited  AEs – reactogenicity  events  occurring  from  the time of each study  vaccination 
(Day 1) through Day 8 after each study vaccination (or until resolved):  
 
a) Injection  site reactions  including  pruritus,  ecchymosis,  erythema,  edema/induration, 
pain, and tenderness.  
 
b) Systemic  reactions  including  fever,  feverishness,  fatigue,  malaise,  myalgia,  arthralgia, 
headache, and nausea.  
 
3. Clinical  safety  laboratory  AEs occurring  from  the time of the first study  vaccination 
through approximately Day 29. Parameters are found in Table 10.  
 
4. Unsolicited  AEs –non-serious  unsolicited  AEs occurring  from  the time of the first study 
vaccination through approximately Day 64.  
 
5. AESIs  (PI[INVESTIGATOR_106279])  and MAAEs  occurring  from  the time of the first study  vaccination 
through approximately Day 380.  
 
Table  4: Safety/Tolerability  Assessment  Timeline  
 
 
Safety/Tolerability 
Evaluation # Day 1 Day 8 Day 15 Day 22 Day 29 Day 64 Day 195 Day 380 
SAEs          
Solicited  AEs*          
Clinical  Safety  Lab AEs         
Unsolicited  non-serious  AEs         
AESIs  (PI[INVESTIGATOR_106279])          
MAAEs          

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
63  
  
#Note  that all visits  after  Visit [ADDRESS_1145211] the schedule assuming that Visit 3 occurs on Day 15.  
 
*Solicited  AEs may require  recording  beyond  Days  [ADDRESS_1145212].  
 
Methods  and Timing  for Assessing,  Recording,  and Analyzing  Safety 
Parameters  
 
9.2.1 Adverse  Events  
 
Adverse  Event  (AE):  ICH E6 (R2) GCP  defines  an AE as any untoward  medical  occurrence  in a 
patient or clinical investigation participant administered a pharmaceutical product and which 
does not necessarily have a causal relationship with this treatment.  The FDA defines an AE as 
any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered drug related.  
 
An AE can therefore  be any unfavorable and unintended sign (including an abnormal laboratory 
finding),  symptom,  or disease  temporally  associated  with the use of a medicinal  (investigational) 
product. The occurrence of an AE may come to the attention of study personnel during study 
visits and interviews of a study recipi[INVESTIGATOR_12189], or upon review by a study 
monitor.  
 
AEs,  including  solicited injection  site and systemic  (subjective and  quantitative)  reactions,  not 
meeting the protocol -defined criteria for SAEs, will be recorded on the appropriate eCRF. 
Information to be  collected for  unsolicited  non-serious  AEs includes event description, date of 
onset, licensed study physician’s assessment of severity and relationship to study product or 
alternate  etiology  (if not related  to study  product)  (assessed  only by [CONTACT_825851] a diagnosis and l isted on the Form FDA 1572 as the site PI [INVESTIGATOR_11637] - 
investigator), date of resolution, seriousness, and outcome. AEs occurring during the trial - 
collection and reporting period will be documented appropriately regardless of relationship to 
study product. AEs  will be followed through resolution.  
 
Any medical condition that is present at the time that the participant is screened will be 
considered  as baseline  and not reported  as an AE. However,  if the severity  of any pre-existing 
medical condition increases, it will be recorded as an AE.  

DMID  Protocol  17-[ADDRESS_1145213]  (see definitions  below). AEs 
characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865]. The 
start and stop date of each reported AE will be recorded on the appropriate eCRF.  
 
Medically -Attended  Adverse  Events  (MAAEs):  For each unsolicited  AE experienced, 
the participant will be asked if he/she had received medical attention, defined as 
hospi[INVESTIGATOR_059], an emergency room visit, or an otherwise unscheduled visit to or from 
medical personnel for any reason. AEs characterized by [CONTACT_825852].  
 
Adverse Events of Special Interest (AESI): An adverse event of special interest 
(serious  or nonserious)  is one of scientific  and medical  concern  specific  to the sponsor’s 
product or program, for which ongoing monitoring and rapid communication by [CONTACT_429447]. Such an event might warrant further 
investigation in order to characterize and understand it. Depending on the nature of the 
event, rapid communication by [CONTACT_50459] (e.g., regulators) might 
also be warranted.  
 
Potentially  Immune -Mediated  Medical  Conditions  (PI[INVESTIGATOR_106279]):  PI[INVESTIGATOR_122754]  a 
group of AEs that includes diseases which are clearly autoimmune in etiology and other 
inflammatory and/or neurologic disorders which may or may not have autoimmune 
etiologies. PI[INVESTIGATOR_825794] B : Adverse Events of Special Interest.  
This is the only category  of AESIs  that will be collected  for this trial. 
 
Protocol  Specified  AESIs:  The only protocol -specific  AESIs  are those  PI[INVESTIGATOR_825795] B.  
 
Severity  of Event:  AEs will be assessed  by a licensed  study  physician  listed  on the Form  FDA 
1572 as the site PI [INVESTIGATOR_11637] -investigator using a protocol -defined grading system (see Sections  
9.2.2 and 9.2.3 ). For events  not included  in the protocol -defined  grading  system,  the following 
guidelines will be used to quantify severity:  
 
• Mild  (Grade  1): Events  require  minimal  or no treatment  and do not interfere  with the 
participant’s daily activities.  
 
• Moderate (Grade 2) : Events result in a low level of inconvenience or concern with 
therapeutic  measures.  Moderate  events  may cause  some  interference  with functioning  and 
daily activities.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
65  
  
• Severe  (Grade  3): Events  interrupt  the participant’s  daily  activities  and may require 
systemic drug therapy or other treatment. Severe events are usually incapacitating.  
 
Relationship to Study Product: The licensed study physician’s assessment of an AE’s 
relationship to study product is part of the documentation process, but it is not a factor in 
determining what is or is not reported in this trial. If there is any doubt as to whether a clinical 
observat ion is an AE, the event should be reported. The relationship to study product must be 
assessed  for AEs using  the terms:  related  or not related. In  a clinical  trial, the study  product  must 
always be suspect. To help assess, th e following guidelines are used:  
 
• Related  – There is a reasonable possibility that the study product caused the AE. 
Reasonable  possibility  means  that there  is evidence  to suggest  a causal  relationship 
between the study product and the AE.  
 
• Not Related  – There  is not a reasonable  possibility  that the administration  of the study 
product caused the event.  
 
9.2.2 Reactogenicity  
 
Reactogenicity events are solicited AEs that are common and known to occur following 
administration  of this type of study  vaccine.  The following  Toxicity  Grading  Scales  will be used 
to grade solicited injection site and systemic (subjective and quantitative) reactions:  
 
Table  5: Injection  Site Reactogenicity  Grading  
 
Injection  Site Reaction  Mild  (Grade  1) Moderate  (Grade  2) Severe  (Grade  3) 
 
Pain – experienced 
without  touching  the 
injection site 
(spontaneous 
discomfort)  Subject is aware of pain, 
but it does not interfere 
with daily activity, and if 
pain medication  is used,  it 
is Over the Counter 
(OTC) and used for less 
than [ADDRESS_1145214]  is aware  of pain; 
there  is interference  with 
daily activity or OTC 
pain medication is used 
for more than [ADDRESS_1145215] is aware of pain, 
but it does not interfere 
with daily activity, and if 
pain medication  is used,  it 
is Over the Counter 
(OTC) and used for less 
than [ADDRESS_1145216]  is aware  of pain; 
there  is interference  with 
daily activity or OTC 
pain medication is used 
for more than [ADDRESS_1145217]  is aware  of pain, 
and it prevents daily 
activity or pain requires 
prescription medication  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
66  
  
Injection  Site Reaction  Mild  (Grade  1) Moderate  (Grade  2) Severe  (Grade  3) 
 
Pruritus   
Does  not interfere  with 
daily activity   
Interferes  with daily 
activity  Prevents  daily  activity  or 
requires prescription 
medication  
 
Ecchymosis  (Bruising)*  Does  not interfere  with 
daily activity  Interferes  with daily 
activity   
Prevents  daily  activity  
 
Erythema  (Redness)*   
Does  not interfere  with 
daily activity   
Interferes  with daily 
activity   
Prevents  daily  activity  
Edema 
(Swelling)/Induration 
(Hardness)*   
Does  not interfere  with 
daily activity   
Interferes  with daily 
activity   
Prevents  daily  activity  
* Will also be measured  in mm but size will not be used as halting  criteria.  
 
Ecchymosis,  erythema  and edema/induration  as analyzed  by [CONTACT_825853]:  
 
Table  6: Injection  Site Reactogenicity  Measurements  
 
Injection  Site Reaction  Small  Medium  Large  
Ecchymosis  (Bruising)*  <20 mm 20 mm – 50 mm >50 mm 
Erythema  (Redness)*  <20 mm 20 mm – 50 mm >50 mm 
Edema  (Swelling)/Induration 
(Hardness)*   
<20 mm  
20 mm – 50 mm  
>50 mm 
* Will not be used as halting  criteria.  
 
Table  7: Subjective  Systemic  Reactogenicity  Grading  
 
Systemic  (Subjective)  Mild  (Grade  1) Moderate  (Grade  2) Severe  (Grade  3) 
 
Feverishness  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
Fatigue  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
Malaise  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
67  
  
Systemic  (Subjective)  Mild  (Grade  1) Moderate  (Grade  2) Severe  (Grade  3) 
 
Myalgia*  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
Arthralgia*  No interference  with 
daily activity  Some  interference  with 
daily activity  Significant  interference, 
prevents daily activity  
 
 
Headache   
No interference  with 
daily activity   
Some  interference  with 
daily activity  Significant interference, 
prevents  daily  activity  or 
headache requires 
prescription medication  
 
 
Nausea   
No interference  with 
daily activity   
Some  interference  with 
daily activity  Significant interference, 
prevents daily activity or 
nausea  requires  prescription 
medication  
* Not at injection  site. 
 
Oral temperature# will be graded  as follows:  
 
Table  8: Quantitative  Systemic  (Oral  Temperature)  Reactogenicity  Grading  
 
Systemic  (Quantitative)  Mild  (Grade  1) Moderate  (Grade  2) Severe  (Grade  3) 
 
Fever*  – oral† 38.0°C  – 38.4°C  
100.4°F  – 101.1°F  38.5°C  – 38.9°C  
101.2°F  – 102.0°F  >38.9°C  
>102.0°F  
# Oral temperature  assessed  on Day [ADDRESS_1145218] study  vaccination  will be considered  as baseline.  
* A fever  can be considered  not related  to the study  product  if an alternative  etiology  can be documented.  
† Participants  must  not eat or drink  anything  hot or cold,  or smoke  within  10 minutes  prior  to taking  oral temperature.  
 
9.2.3 Additional  Adverse  Event  Severity  Grading  
 
Pulse  and BP# will be graded  as follows:  
 
Table  9: Pulse  and BP Adverse  Event  Grading  
 
Physiologic  Parameter  Mild  (Grade  1) Moderate  (Grade  2) Severe  (Grade  3) 
Bradycardia  – beats  per minute  45 – 50 40 – 44 <40 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
68  
  
Tachycardia  – beats  per minute  101 – 130 131 – 155 >155  
Hypotension  (systolic)  mmHg  80 – 84 75 – 79 <75 
Hypotension  (diastolic)  mmHg  50 – 54 45 – 49 <45 
Hypertension  (systolic)  mmHg  141 – 155 156 – 160 >160  
Hypertension  (diastolic)  mmHg  91 – 100 101 – 110 >110  
# Pulse  and BP assessed  on Day [ADDRESS_1145219] study  vaccination  will be considered  as baseline.  
 
Clinical  safety  laboratory values  will be graded  as follows:  
 
Table  10: Clinical  Safety  Laboratory  Adverse  Event  Grading  
 
Panel  and Analytea Mild  (Grade  1) Moderate  (Grade 
2) Severe  (Grade 
3) 
Serum  Chemistry  
Blood  Urea  Nitrogen  (mg/dL)  23–26 27–31 >31 
Creatinine  (mg/dL)  female  1.3–1.7 1.8–2.0 >2.0 
Creatinine  (mg/dL)  male 1.4–1.7 1.8–2.0 >2.0 
Alkaline  phosphatase  (U/L) 
female  147-196 197-294 >294  
Alkaline  phosphatase  (U/L) 
male 192-256 257-384 >384  
ALT(U/L)  68-113 114-225 >225  
Total Bilirubin when 
accompanied  by [CONTACT_825854] (mg/dL)  1.3-1.6 1.7-2.0 >2.0 
Total Bilirubin when not 
accompanied  by [CONTACT_825854] (mg/dL)  1.3-2.0 2.1-2.6 >2.6 
Hematology  
Hemoglobin,  female  (g/dL)  10.0-10.9 9.0-9.9 <9.0 
Hemoglobin decrease from 
baseline  value,  female  (g/dL)  1.0–1.5 1.6–2.0 >2.0 
Hemoglobin,  male  (g/dL)  11.5-12.4 10.5-11.4 <10.5  
Hemoglobin  decrease  from 
baseline  value,  male  (g/dL)  1.0–1.5 1.6–2.0 >2. 0 
WBC  (leukocytosis) 
(cell/mm3) 12,001 –15,000  15,001 –20,000  >20,000  
WBC  (leukopenia)  (cell/mm3) 2,500 –2999  1,500 –2,499  <1,500  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
69  
  
Panel  and Analytea Mild  (Grade  1) Moderate  (Grade 
2) Severe  (Grade 
3) 
Eosinophils (absolute 
eosinophilia)  (cell/mm3) 1201 -1500  1,501 –5,000  >5,000  
Neutrophil  (neutropenia) 
(cell/mm3) 1001 -1200  751-1,000  <751  
Platelets 
(thrombocytopenia)(cell/mm3) 100,000 – 
126,000  50,000 -99,999  <50,000  
ALT  = alanine  aminotransferase;  WBC  = white  blood  cell. 
a Laboratory normal reference ranges have been taken into consideration for the toxicity grading scale.  If the laboratory provides 
a value  that has additional significant  digits  beyond  what  is provided  in the table,  digits of  0-4 will be rounded  down  and digits  of 
5-9 will be rounded up, for purposes of delineating a grade.  
 
9.2.4 Serious  Adverse  Events  
 
Serious  Adverse  Event  (SAE) : An AE or suspected  adverse  reaction  is considered  “serious”  if, 
in the view of either the site PI (or appropriate sub -investigator) or sponsor, it results in any of 
the following outcomes:  
 
• Death,  
 
• A life-threatening  AE*,  
 
• Inpatient  hospi[INVESTIGATOR_40088],  
 
• A persistent  or significant  incapacity  or substantial  disruption  of the ability  to conduct 
normal life functions, or  
 
• A congenital  anomaly/birth  defect.  
 
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_12190], based upon appropriate medical 
judgment they may jeopardize the patient or participant and may require medical or 
surgical  intervention  to prevent  one of the outcomes  listed  in this definition. Examples  of 
such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
 
* Life-threatening  AE: An AE is considered “life -threatening”  if, in the view  of either  the site PI 
(or appropriate sub -investigator) or sponsor, its occurrence places the patient or participant at 
immediate risk of death. It does not include an AE that, had it occurred in a more severe form, 
might have caused death.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
70  
  
SAEs  will be: 
 
• Assessed  for severity  and relationship  to study  product  or alternate  etiology  (if not related 
to study product) by a licensed study physician listed on the Form FDA 1572 as the site 
PI [INVESTIGATOR_11637] -investigator.  
 
• Recorded  on the appropriate  SAE  form  and entered  into the eCRF.  
 
• Followed  through  resolution  by a licensed  study  physician  listed  on the Form  FDA  1572 
as the site PI [INVESTIGATOR_11637] -investigator.  
 
• Reviewed  and evaluated  by [CONTACT_4484]  (periodic  review  unless  related),  DMID,  and IRB, 
as required.  
 
9.2.[ADDRESS_1145220] Values  or 
Abnormal Clinical Findings  
 
The site PI [INVESTIGATOR_122747]-investigator  is responsible  for recording  all AE/SAEs  that are 
observed  or reported  during  this trial, regardless  of relationship  to study  product.  AE/SAEs, 
abnormal laboratory test values, or abnormal clinical findings will be collected, assessed, 
documented, reported, and followed appropriately, using a local laboratory as necessary. In 
determining eligibility, refer to Section 5.[ADDRESS_1145221] study 
vaccination through approximately Day 64.  
 
MAAEs, SAEs, and AESIs (PI[INVESTIGATOR_106279]) will be documented and reported from the time of the 
first study vaccination through approximately 12 months after the second study vaccination (the 
entire  time the participant  is followed  from  first vaccination  until study  completion),  i.e., through 
approximately Day 380.  

DMID  Protocol  17-[ADDRESS_1145222]  be submitted  immediately  (within 
24 hours of site awareness) on an SAE form to the DMID Pharmacovigilance Group, at the 
following address:  
DMID  Pharmacovigilance  Group  
Clinical  Research  Operations  and Management  Support  (CROMS) 
[ADDRESS_1145223]. Suite 650  
Bethesda,  MD [ZIP_CODE],  [LOCATION_003]  
SAE  Hot Line:  [PHONE_2618]  (US)  or [PHONE_2619]  (outside  US) 
SAE FAX: 1 -[PHONE_1729] (US) or 1 -[PHONE_891] (outside US)  
SAE  Email  Address:  [EMAIL_1393]  
 
In addition  to the SAE  form,  selected  SAE  data fields  must  also be entered  into Advantage 
eClinicalSM. Please see the protocol -specific MOP for details regarding this procedure.  
 
Other  supporting  documentation  of the event  may be requested  by [CONTACT_122831].  
 
The DMID  Medical  Monitor  and DMID  Clinical  Project  Manager  will be notified  of the SAE  by 
[CONTACT_71500].  
 
The DMID  Medical  Monitor  will review  and assess  the SAE  for regulatory  reporting  and 
potential impact on participant safety and protocol conduct.  
 
At any time after completion  of this trial, if the site PI [INVESTIGATOR_122747]-investigator  becomes 
aware  of an SAE  that is suspected  to be related  to study  product,  the site PI  [INVESTIGATOR_122747]- 
investigator will report the event to the DMID Pharmacovigilance Group.  
 
9.3.2 Regulatory  Reporting  for Studies  Conducted  Under  DMID -Sponsored  IND 
 
Following notification from the site PI [INVESTIGATOR_29353] -investigator, DMID, the 
Investigational New Drug (IND) sponsor, will report any suspected adverse reaction that is both 
serious and unexpected. DMID will report an AE as a suspected adverse reactio n only if there is 
evidence to suggest a causal relationship between the drug and the AE. DMID will notify the 
FDA and all investigators (i.e., the participating VTEU site PI  [INVESTIGATOR_825796](s)  or under  any PI’s IND(s))  in an IND safety  report  of potential  serious  risks 
from clinical trials or any other source, as soon as possible, but in no case later than 15 calendar 
days after the sponsor determines that the information qualifies for reporting as specified in 21  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
72  
  
CFR Part 312.32. DMID will also notify the FDA of any unexpected fatal or life -threatening 
suspected  adverse  reaction  as soon  as possible,  but in no case later than 7 calendar  days after the 
sponsor’s initial receipt of the information. Relevant follow up information to an IND safety 
report will be submitted as soon as the information is available. Upon request from the FDA, 
DMID will submit to the FDA any additional data or information th at the agency deems 
necessary, as soon as possible, but in no case la ter than [ADDRESS_1145224].  
 
All serious  adverse  events  designated  as “not related”  to study  product(s)  will be reported  to the 
FDA at least annually in a summary format.  
 
9.3.3 Reporting  of Pregnancy  
 
Upon  awareness,  pregnancies  occurring  in participants  will be recorded  on the Pregnancy  Report 
eCRF. All pregnancies reported during the course of this trial will be followed to pregnancy 
outcome, if allowable to the participant. With the participant’s permission, we will continue to 
follow the participant for safety and immune response. If the participant be comes pregnant after 
the first vaccination, the second vaccination will not be given.  
 
Type  and Duration  of Follow -up of Participants  after  Adverse  Events  
 
Non-serious  unsolicited  AEs will be collected,  assessed,  and followed  through  resolution  from 
the time of first study vaccination through approximately Day 64.  
 
MAAEs,  SAEs,  and AESIs  (PI[INVESTIGATOR_106279])  will be collected,  assessed  and followed  from  the time of 
the first study vaccination through resolution even if this extends beyond the trial -reporting 
period (approximately 12 months after the second study vaccination, i.e., approximately Day 
380).  
 
Resolution  of an AE/SAE  is defined  as the return  to pretreatment  status  or stabilization  of the 
condition with the expectation that it will remain chronic.  
 
Follow -up procedures,  evaluations,  and outcomes  will be recorded  on the appropriate  eCRF.  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
73  
  
Halting  Rules  
 
9.5.1 Individual  Halting  Rules  
 
• Any participant experiences ulceration, abscess, or necrosis at the injection site from 
vaccination  until 7 days later (Days  [ADDRESS_1145225] vaccination  and 
Days 15 through 22, inclusively, for the second vaccination. Should the second 
vaccination occur after Day 15, the reactogenicity period will occur from the day of 
vaccination until 7 days later)  
 
• Any participant  experiences  laryngospasm,  bronchospasm,  or anaphylaxis  within  24 
hours after administration of the study products  
 
• Any participant  experiences  generalized  urticaria  (defined  as urticarial  lesions  occurring 
at more than two body parts) within [ADDRESS_1145226].  
 
• Any participant  experiences  an SAE  (except  for accident  or trauma)  after administration 
of the study product.  
 
• Any participant  experiences  a grade  3 AE including  lab, local,  or systemic  solicited 
reactogenicity events (excluding measured grades of ecchymosis, erythema, and 
edema/induration alone)  
 
9.5.2 Study  Halting  Rules  
 
 
Additional  enrollment  and study  interventions/administration  of study  products  in this trial will 
be halted for SMC review/recommendation if any of the following are reported after the first 
study vaccination:  
 
• Any participant experiences ulceration, abscess or necrosis at the injection site in the 
week after vaccination (Days [ADDRESS_1145227] vaccination and Days 
15 through 22, inclusively, for the second vaccination; should the second vac cination 
occur  after Day 15, the reactogenicity  period  will occur  from  the day of vaccination  until 
7 days later) that is considered related to study product administration.  
 
• Any participant  experiences  laryngospasm,  bronchospasm  or anaphylaxis  within  [ADDRESS_1145228].  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
74  
  
• Two or more  participants  experience  generalized  urticaria  (defined  as urticarial  lesions 
occurring at more than two body parts) within [ADDRESS_1145229].  
 
• Any participant  experiences  an SAE  after administration  of study  product  that is 
considered related to study product.  
 
• Any participant  develops  a PI[INVESTIGATOR_825797] (approximately Day 380).  
 
• Three  or more  participants  experience  a grade  3 injection  site or systemic  solicited 
adverse event (excluding measured grades of ecchymosis, erythema, and 
edema/induration alone).  
 
• Three  or more  participants  experience  the same  grade  3 AE (unsolicited  and laboratory 
abnormality), in the same HLGT by [CONTACT_373929], considered related to study 
product.  
 
Grading  scales  for solicited  injection  site and systemic  (subjective  and quantitative)  reactions  are 
included in Section 9.2.2 . Grading scales for clinical safety laboratory AEs are included in 
Section 9.2.3 . 
 
If any of the halting  rules  are met following  any participant  receipt  of study  vaccination,  then this 
trial will not continue with the remaining enrollments or study vaccinations without a review by 
[CONTACT_319680].  
 
DMID  retains  the authority  to suspend  additional  enrollment,  study  interventions,  and 
administration of study products during this trial, as applicable.  
 
The DMID  Medical  Monitor  is empowered  to stop enrollment  and study  vaccinations  if AEs that 
meet the halting criteria are reported.  
 
Safety  Oversight  
 
9.6.1 Independent  Safety  Monitor  (ISM)  
 
For this clinical trial, an ISM is not required . The site PI [INVESTIGATOR_29353] -investigator will 
send to the DMID  Medical  Monitor  a summary  of the events  and include  the site PI [INVESTIGATOR_124181].  

DMID  Protocol  17-[ADDRESS_1145230] of members with appropriate expertise to 
contribute to the interpretation of the data from this trial.  
 
The SMC will operate under the rules of a DMID -approved charter that will be written at the 
organizational  meeting  of the SMC.  At this time,  each data element  that the SMC  needs  to assess 
will be clearly  defined.  Procedures  for SMC reviews/meetings  will be defined  in the charter. The 
SMC will review applicable data to include, but not limited to, study progress and clinical, 
safety, reactogenicity, and immunogenicity data. Reports may include enrollment and 
demographic information, medical history, concomitant medications,  physical assessments, 
clinical  laboratory  values,  dosing  compliance,  solicited  and unsolicited  AEs,  MAAEs,  SAEs,  and 
AESIs (PI[INVESTIGATOR_106279]). The SMC will review SAEs on a regular basis and ad hoc during t his trial.  
The DMID  Medical  Monitor  will be responsible  for reviewing  SAEs  in real time.  
 
The SMC  will conduct  the following  reviews:  
 
• An Organizational  Meeting  that occurs  prior  to participant  enrollment  
 
• Ad hoc when a halting rule is met, or DMID/SMC chair may convene an ad hoc meeting 
if there  are immediate  concerns  regarding  observations  during  the course  of this trial. The 
DMID Medical Monitor is empowered to stop enrollment and study vaccinations if AEs 
that meet the halting criteria are reported.  
 
• Final review meeting: [ADDRESS_1145231] the treatment assignment be 
unblinded for an individual participant if required for safety assessment. The SMC will review 
grouped and unblinded data in the closed session only. As an outcome of each review/meeting, 
the SMC will make a recommendation as to the advisability of proceeding with study 
vaccinations, as applicable, and to continue, mo dify or terminate this trial.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
76  
  
10 CLINICAL  MONITORING  
 
Site Monitoring  Plan  
 
Site monitoring is conducted to ensure that the human participants’ protections, study and 
laboratory  procedures,  study  interventions/administration  of study  products,  and data collection 
processes are of high quality and meet sponsor and ICH E6 GCP guidelines and applicable 
federal regulations, and that this trial is conducted in accordance with the protocol, protocol - 
specific  MOP  and applicable  sponsor  SOPs.  DMID,  the sponsoring  agency,  or its designee  will 
conduct site -monitoring visits as detailed in t he clinical monitoring plan. DMID -designated 
clinical monitors will verify that this trial is conducted, and data are generated, documented 
(recorded), and reported in compliance with the protocol, ICH E6 GCP guidelines, and 
applicable regulatory requirements. Clinical monitoring reports will be submitted to DMID.  
 
Site visits will be made at standard intervals as defined by [CONTACT_122863].  Monitoring  visits  will include,  but are not limited  to, review  of 
regulatory files, accountability records, eCRFs, ICFs, medical and laboratory reports, and 
protocol and GCP compliance. Site monitors will have access to each participating VTEU site, 
study personnel, and all study documentation according to the DMID -approved site monitoring 
plan.  Study  monitors  will meet  with site PIs to discuss  any problems  and actions  to be taken  and 
document visit findings and discussions.  

DMID  Protocol  17-[ADDRESS_1145232] 
participant vaccinated until the final participant receives his/her first vaccination.  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
78  
  
A total of 40 participants will be enrolled. Assuming up to 10% drop out by [CONTACT_2006] 64, it is 
expected  that at least [ADDRESS_1145233],  based  on 
the planned sample size of N=20 participants per study arm.  
 
Table 11 indicates the probability of observing one or more safety events, such as solicited 
injection  site or systemic  reactogenicity  events  or an unsolicited  AE of a particular  type,  for a 
single treatment arm (N=20), and for all enrolled subjects (N=40).  
 
Table  11: Probability  (%) to Detect  Safety  Events  Emmes  
 
 
Event 
Frequency  N = 20 N = 40 
≥10%  
Very  Common  87 98 
≥1% 
Common  18 33 
≥0.1%  
Uncommon  1 3 
≥0.01%  
Rare <0.1 <0.1 
 
 
Binomial  confidence  intervals  (CI) are widest  (have  the least precision)  when  the response  rate is 
50%. Table [ADDRESS_1145234] 
(Clopper -Pearson) binomial confidence intervals.  
 
 
Table  12: Precision  of Binomial  Confidence  Intervals  
 
N 95% CI 
20 27-73 
40 34-66 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
79  
  
For each of the primary  immunogenicity  objectives,  a power  analysis  is provided  below  for 
testing the following hypotheses with the planned sample size, where p c = probability of 
response in comparator arm; where p e = probability of response in experimental arm.  
 
Test for difference  in proportion responders:  
H0: pc – pe = 0 – No difference  in response  probabilities 
H1: pc – pe ≠ 0 – difference in response probabilities  
 
Table 13 illustrates the minimum detectable differences in the probability of responding (e.g., 
attaining seroconversion or NF 50 ≥0.56 [seroprotection]) between participants who receive 
AV7909 as the lyophilized formulation or  liquid formulation using a  two-sided likelihood ratio 
test with 80% power and alpha = 0.05. It is assumed that up to 10% of subjects (N=2) will be 
excluded  from  the per-protocol  analysis  in each group.  Seroconversion  rates  of 10% to 60% are 
considered.  
 
Table  13: Minimum  Detectable  Difference  in the Probability  of Response  with  80%  Power  
 
 
N per Group   
Probability of 
Response in 
Comparator  Group  A  
80%  Power  
 
Minimal 
Detectable 
Difference   
Probability  of 
Response in 
Experimental 
Group B  
 
 
 
 
 
 
 
N = 18  
0.10  
0.39  
0.49 
 
0.20  
0.43  
0.63 
 
0.30  
0.43  
0.73 
 
0.40  
0.42  
0.82 
 
0.50  
0.39  
0.89 
 
0.60  
0.35  
0.95 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
80  
  
Planned  Interim  Analyses  
No interim  analyses  are planned.  
 
11.5.1  Interim  Safety  Review  
An interim  safety  review  may include  enrollment  and demographic  information,  medical  history, 
concomitant medications, physical assessments, clinical laboratory values, dosing compliance, 
and solicited and unsolicited AE/SAEs. Additional data may be requested by [CONTACT_4484], and 
interim statistical reports may be  generated as deemed necessary and appropriate by [CONTACT_122830]. The 
SMC may receive data in aggregate and presented by [CONTACT_2939], including expected and 
observed rates of the expected AEs. The SMC will review grouped data in the closed session 
only. The SMC wil l meet and review this data at scheduled time points or ad hoc as needed 
during this trial as defined in the SMC charter. As an outcome of each review/meeting, the  
SMC  will make  a recommendation  as to the advisability  of proceeding  with study  vaccinations 
(as applicable), and to continue, modify, or terminate this trial.  
 
Additionally,  this trial will be monitored  to determine  if any of the halting  rules  described  in 
Section 9.[ADDRESS_1145235] participant’s 
last visit is completed, the final clinical database including all long -term safety follow -up data is 
cleaned, monitored and locked, and all primary and seco ndary immunogenicity data are 
available. There are no planned exploratory immunogenicity endpoints. If any are added via 
protocol  amendment,  then the additional  exploratory  immunogenicity  endpoint  data not available 
at the time of CSR preparation may be in cluded in an addendum to the CSR.  
 
A formal  statistical  analysis  plan which  defines  the analyses  to be included  in the expedited 
report and the final CSR will be developed, finalized, and submitted to the FDA, prior to 
unblinding for any analysis.  
 
11.6.[ADDRESS_1145236] dose of study 
vaccine.  
 
The modified intent -to-treat (mITT) population includes all randomized participants who 
received  the first dose of study  vaccine  and contributed  at least one post-first study  vaccination 
venous blood sample for immunogenicity testing for which valid results were reported. For  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
81  
  
analyses  using  the mITT  population,  participants  will be grouped  based  on randomized  treatment 
arm. 
 
The per protocol  (PP) population  includes  all participants  in the mITT  with the following 
exclusions:  
• Data  from all  available  visits  for participants  found  to be ineligible  at baseline.  
• Data  from  all visits  for participants  that did not contribute  venous  blood  samples  for 
immunogenicity testing.  
• Data  from  all visits  subsequent  to major  protocol  deviations,  such as: 
o Second  vaccination  not received  
o Second  vaccination  received  out of window  
o Receipt of immunosuppressive therapy (e.g., corticosteroids) within [ADDRESS_1145237] study vaccination.  
o Receipt  of non-study  licensed  live vaccine  within  30 days before  or after each 
study vaccination.  
o Receipt  of non-study  licensed,  inactivated  vaccine  within  14 days before  or 
after each study vaccination.  
• Data  from  any visit that occurs  substantially  out of window.  
 
For analyses  using  the PP population,  participants  will be grouped  based  on study  vaccinations 
received.  
 
11.6.2  Safety  Data  
 
Summaries  and analysis  of safety  data will be presented  for the Safety  Analysis  Population.  All 
summaries and analyses will be presented for all participants.  
 
Solicited AEs will be summarized by [CONTACT_825855] (through [ADDRESS_1145238] 
study  vaccination,  Days  1 through  8 and Days  15 through  22) and as the maximum  severity  over 
all days. Additionally, solicited AEs will be analyzed by [CONTACT_825856] -up period, dichotomizing into a binary variable (none versus mild, moderate, or 
severe) and using standard techniques, such as exact confidence intervals, to summarize the 
proportion of subjects reporting each symptom, any i njection site symptom, and any systemic 
symptom.  Summaries  of solicited  AEs will be presented  for each study  vaccination  by [CONTACT_54012]. The proportion of participants reporting symptoms may be compared between treatment 
arms using Chi -square or Fisher’s  exact test.  
 
Unsolicited  AEs will be coded  by [CONTACT_527016]  (MedDRA) for 
preferred term and system organ class (SOC). The numbers of SAEs, MAAEs, and AESIs  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
82  
  
(PI[INVESTIGATOR_106279])  are likely  to be small  in this trial and will be reported  by [CONTACT_825857], MedDRA preferred term and SOC, relevant dates (study vaccinations and 
AEs), severity, relatedness, and outcome for each event. Non -serious unsolicited AEs will be 
summarized as number and percentage of participants reporting at least one event in each 
MedDRA preferred term and SOC, cross tabulated by [CONTACT_202438]. Additionally, the proportion of participants and exact 95% confidence intervals of AEs 
in aggre gate and by [CONTACT_61132] categories will be computed.  
 
Clinical  laboratory  data will be summarized  by [CONTACT_825858] -study vaccination visits. Graphical presentations may include box plots.  
 
11.6.3  Humoral  Immunogenicity  Data  
 
Summaries and analysis of immunogenicity data will be presented for the mITT and PP 
populations; the PP population will be considered the primary analysis. Immune responses in 
terms  of TNA  ED 50 and NF 50, and anti-PA IgG by [CONTACT_825859]. Analysis at all time points will include geometric mean titers (GMTs) and 
proportion  of participants  with seroconversion  (defined  as ≥4-fold increase  over baseline  levels, 
or a ≥4 -fold increase over the LLOQ if the baseline value is <LLOQ). Additionally, the 
proportion of subjects in each study group with putative seroprotection (defined as NF 50≥0.56) 
will be assessed at each time point. All summaries will include the corresponding 95% 
confidence interval. No exploratory immunologic outcomes are anticipated.  
 
11.6.[ADDRESS_1145239] of including or excluding the outliers. Any substantive differences in these analyses will 
be reported.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
83  
  
12 DATA  COLLECTION  FORMS  AND  ACCESS  TO SOURCE 
DATA/DOCUMENTS  
 
The participating VTEU site will maintain appropriate medical and research records for this 
clinical trial, in compliance with ICH E6 GCP Section 4.9 and regulatory and institutional 
requirements for the protection of confidentiality of participants. The p articipating VTEU site 
will permit the study monitor or other authorized representatives of DMID as well as 
governmental regulatory agencies, such as the FDA, to examine (and when required by 
[CONTACT_1289], to copy) clinical trial records for the purposes  of quality assurance reviews, 
audits, monitoring and evaluation of the study safety and progress. These representatives will be 
permitted access to all source data, which include, but are not limited to, hospi[INVESTIGATOR_1097],  
clinical and office charts, laboratory notes, memoranda, evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_122769],  microfiches,  photographic  negatives,  microfilm 
or ma gnetic media, x -rays, and participant files, and records kept at the pharmacy, at the 
laboratories and medico -technical departments involved in this clinical trial. Source data are all 
information, original records of clinical findings, observations, or ot her activities in a clinical 
trial necessary for the reconstruction and evaluation of the clinical trial.  
 
Interview  of participants  is sufficient  for obtaining  medical  history.  Solicitation  of medical 
records from the participant’s primary care provider is not required.  
 
The study uses direct data entry for the participating clinic site and a web -based electronic 
Memory Aid (eMemory Aid) for participants. All eCRFs serve as the source documents. 
Participants will be trained to use a database to complete a web based “eMemor y Aid” and are 
expected to enter information in the eMemory Aid each day.  Participants using the eMemory 
Aid will also be provided  a paper  memory  aid for their use in the event  they are  unable  to access 
the web -based system.  The participants will be asked to enter the information from the paper 
memory aid into the eMemory Aid once they are able to access the web -based system.  
 
Participants  will record  temperature,  local  and systemic  symptoms,  and if any new medications 
were  used following  vaccination  or changes  to previously  reported  medications  daily  for 8  days 
after any vaccination (Days 1 through 8 and Days 15 through 22).  
 
Participants will be instructed to contact [CONTACT_825860],  for prompt  follow -up in real time.  The study 
clinic will be alerted in real time of any potential solicited events of Grade [ADDRESS_1145240] of all authorized data originators, including site staff, will be 
included on the Study Personnel/Signature [CONTACT_122868].  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
85  
  
13 QUALITY  CONTROL  AND  QUALITY  ASSURANCE  
 
Following a written DMID -accepted site quality management plan, each participating VTEU site 
(and its subcontractors) is responsible for conducting routine quality assurance (QA) and quality 
control  (QC)  activities  to internally  monitor  study  progress  and protocol  compliance. Each  site PI 
[INVESTIGATOR_71464] -related sites, source data/eCRFs and reports for the  
purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_90471].  Each  site PI [INVESTIGATOR_825798].  
 
The SDCC  will implement  QC procedures  beginning  with the data entry  system  and generate 
data QC checks that will be run on the database. Any missing data or data anomalies will be 
communicated to the participating VTEU site(s) for clarification and resolution.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
86  
  
14 ETHICS/PROTECTION  OF HUMAN  PARTICIPANTS  
 
Ethical  Standard  
 
The site PI [INVESTIGATOR_462195]: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research (National Commission for the Protection of Human Subjects of B iomedical and 
Behavioral  Research  [April  18, 1979])  and codified  in [ADDRESS_1145241]  (IRB)  
 
The institution engaged in this research will hold a current Federal Wide Assurance (FWA) 
issued  by [CONTACT_154430]  (OHRP)  for federally  funded  research.  The 
IRB must be registered with OHRP [OHRP -only or OHRP/FDA] as applicable to the research. 
The IRB FWA number will be provided to DMID.  
 
The site PI [INVESTIGATOR_149059]/her research site(s) 
and send supporting documentation to DMID before initiating recruitment of participants. The 
site PI [INVESTIGATOR_825799],  to conduct 
the review in accordance with 45 CFR 46, ICH E6 GCP guidelines, and as applicable, 21 CFR 
56 (Institutional Review Boards), 21 CFR 50 (Protection of Human Subjects), and other  federal, 
state, and local regulations and guidance. IRB approved recruitment process, screening script, 
and materials for participants may be utilized.  DMID must receive the documentation that 
verifies IRB approval for this protocol, associated informed consent documents, and upon 
request, any recruitment material and handouts or surveys intended for the participants, prior to 
the recruitment and enrollme nt of participants.  
 
Any amendments to the protocol or consent materials will be approved by [CONTACT_12228].  IRB review  and approval  will occur  at least annually  throughout  the enrollment 
and follow -up of participants and may cease if annual review is no longer required by [CONTACT_106887]. The site PI [INVESTIGATOR_825800].  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
87  
  
Informed  Consent  Process  
 
Informed consent is a process that is initiated prior to an individual agreeing to participate in a 
trial and continuing throughout the individual’s trial participation. During recruitment, potential 
participants may be screened for eligibility by [CONTACT_825861], 
per an IRB -approved process that ensures confidentiality.  At the first clinic visit, before any 
study  procedures  are performed,  informed  consent  will be obtained  and documented.  Participants 
will receive a concise a nd focused presentation of key information about the trial, verbally and 
with a written ICF. The explanation will be organized and presented in lay terminology and 
language that facilitates understanding why one might or might not want to participate. The ICF 
must not include any exculpatory statements.  
 
The site PI [INVESTIGATOR_825801]-to-face.  The 
key information about the purpose of the trial, the procedures and experimental aspects of the 
trial, risks and discomforts, any expected benefits to the participants, and alternative treatment 
will be presented first to the participant.  
 
Participants will also receive an explanation that the trial involves research and a detailed 
summary of the proposed study procedures and study interventions/study products. This 
discussion will include aspects of the trial that are experimental, the prob ability for random 
assignment  to treatment  arms,  any expected  benefits,  all possible  risks  (including  a statement  that 
the particular treatment or procedure may involve risks to the participant or to the embryo or 
fetus, if the participant is or may become  pregnant, that are currently unforeseeable), the 
expected duration of the participant’s participation in the trial, alternative treatment/procedures 
that may be available, and  the important  potential  benefits  and risks  of these  available alternative 
treatment/procedures.  
 
Participants will be informed that they will be notified in a timely manner if information 
becomes available that may be relevant to their willingness to continue participation in the trial. 
Participants will receive an explanation as to whether any compen sation and any medical 
treatments are available if injury occurs, and, if so, what they consist of or where further 
information  may be obtained.  Participants  will be informed  of the anticipated  financial  expenses, 
if any, for participating in the trial, as  well as any anticipated prorated payments, if any, to the 
participant for participating in the trial. They will be informed of whom to contact (e.g., the site 
PI) for answers to any questions relating to the research project.  
 
Information will also include the foreseeable circumstances and/or reasons under which the 
participant’s  participation  in the trial may be terminated.  The participants  will be informed  that 

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
88  
  
participation  is voluntary  and that they are free to withdraw  from  the study  for any reason  at any 
time without penalty or loss of benefits to which he or she is otherwise entitled.  
 
The extent  of the confidentiality  of the participant’s  records  will be defined,  and participants  will 
be informed that applicable data protection legislation will be followed. They will be informed 
that the monitors, auditors, IRB, NIAID, and regulatory authorities will be granted direct access 
to their original medical records for verification of tri al procedures and/or data without violating 
the confidentiality of the participant, to the extent permitted by [CONTACT_6988], and that, by [CONTACT_2960] a writte n ICF, the participant is authorizing such access.  
Participants  will be informed  that records  identifying  them  will be kept confidential  and, to the 
extent permitted by [CONTACT_29695]/or regulations, will not be  made  publicly available 
and, if the results of the trial are published, the participant’s identity will remain confidential. 
Participants will be informed whether private information collected from this research and/or 
samples/specimens will be used for additional research, even if ident ifiers are removed.  
Participants will be allowed sufficient time to consider participation in the trial and have the 
opportunity  to discuss  the trial with their family,  friends,  or legally  authorized  representative,  or 
think about it prior to agreeing to participate.  
 
ICFs will be IRB -approved and participants will be asked to read and review the ICF. 
Participants  must  sign the ICF prior  to starting  any study  procedures  being  done  specifically  for 
the trial. Once signed, a copy of the ICF will be given to the participants for their records. The 
participant(s) may withdraw consent at any time throughout the course of the trial. Their rights 
and welfare  will be protected by [CONTACT_825862].  
 
New information that significantly impacts the participant’s risk of receiving the study 
interventions/study products will be communicated by [CONTACT_7880] [INVESTIGATOR_022]/her designees to the 
participants  who consent  to participate  in the trial in accordance  with IRB requirements.  The ICF 
will be updated and participants will be re -consented in accordance with IRB requirements, if 
necessary. Participants will be given a copy of all ICFs that they sign.  
 
 
Exclusion  of Women,  Minorities  and Children  (Special  Populations)  
 
This trial will be inclusive of all interested persons, 18 to 45 years of age, who meet the 
Participant Inclusion Criteria (see Section 5.1.1 ) and do not meet the Participant Exclusion 
Criteria  (see Section  5.1.2 ), regardless  of religion,  sex or ethnic  background.  Should  the outcome 
of this trial be deemed acceptable, additional trials may be initiated including those in other 
populations.  

DMID  Protocol  17-[ADDRESS_1145242]  utilize  a highly  effective  method  of contraception that  is defined  as one that results  in a low 
failure rate (i.e., less than 1% per year) when used consistently and correctly (effective methods 
of birth control are outlined in the inclusion criteria, section 5.1.1 ). In addition to contraceptive 
use, all females of childbearing potential will be required to have a negative pregnancy test 
within  [ADDRESS_1145243] by [CONTACT_7880], other study personnel, the 
sponsor, and their agents. This confidentiality includes documentation, investigation data, 
participant’s  clinical  information,  and all other  information  generated  during  participation  in this 
trial. No information  concerning  this trial, or the data generated  from  this trial will be released  to 
any unauthorized third party without written consent of the participant and approval by [CONTACT_122830].  
 
Participant confidentiality will be maintained when trial results are published or discussed in 
conferences and is extended to cover testing of samples/specimens. The  study monitor or other 
authorized representatives of DMID as well as governmental regulatory agencies, such as the 
FDA, may inspect all documents and records required to be maintained by [CONTACT_90474]. This 
includes,  but is not limited  to, medical  records  (office,  clinic  or hospi[INVESTIGATOR_307])  and pharmacy records 
for the participants in  this trial.  The participating VTEU  site will permit  access  to such records. 
All records  will be kept locked  and all computer  entry  and networking  programs  will be carried 
out with coded numbers only and with password -protected systems. All non -clinical 
samples/specimens, evaluation forms, reports, and other records that leave the site will be 
identified only by a coded number and will not be identified by [CONTACT_126727]’s name.  
 
To protect privacy, we  have received a Certificate of Confidentiality. With this Certificate, the 
researchers cannot be  forced to release  information that may identify the participant, even by a 
court  subpoena,  in any federal,  state or local  civil,  criminal,  administrative,  legislative,  or other 
proceedings.  The researchers  will use the Certificate  to resist  any demands  for information  that 
would identify the participant, except as explained below.  

DMID  Protocol  17-[ADDRESS_1145244] be released in order to meet the requirements of the FDA.  
 
A Certificate of Confidentiality does not prevent the participant from voluntarily releasing 
information about themselves or their involvement in this research. If any person or agency 
obtains  a written  consent  to receive  research  information,  then the researchers  may not use the 
Certificate to withhold that information.  
 
The Certificate of Confidentiality does not prevent the researchers from reporting without the 
participant’s consent, information that would identify the participant as a participant in the 
research  project  regarding  matters  that must  be legally  reported  including:  child  and elder  abuse, 
sexual abuse or wanting to harm themselves or others.  
 
Study  Discontinuation  
 
If this trial is prematurely terminated by [CONTACT_456], any regulatory authority, the site PI, or 
appropriate sub -investigator for any reason, the site PI [INVESTIGATOR_29353] -investigator will 
promptly inform the participants and assure appropriate therapy or follow -up for them, as 
necessary.  The site PI [INVESTIGATOR_122747]-investigator  will provide  a detailed  written  explanation 
of the termination to the IRB. If any participant’s private information will continue to be 
collected for this trial, the IRB must approve an ICF with the study procedures, any risks and 
discomforts as well as applicable elements, and the site PI [INVESTIGATOR_294988] -consent the 
participants as approved by [CONTACT_1201].  
 
If this trial is discontinued, participants who have signed the ICF  and are randomized and 
vaccinated  will continue  to be followed  for safety for  the duration  of the prescribed  safety 
follow -up period. No further study vaccinations will be administered.  
 
Costs,  Participant  Compensation  and Research  Related  Injuries  
 
There  is no cost to participants  for the research  tests,  study  procedures/evaluations  or study 
vaccines while taking part in this trial.  
 
Participants  may be compensated  for their participation  in this trial.  Compensation  will be in 
accordance with local IRB requirements, and subject to local IRB approval.  
 
If it is determined by [CONTACT_825863] [INVESTIGATOR_122767] a 
participant  as a direct  result  of the tests or treatments  that are done  for this trial,  then referrals  to 

DMID  Protocol  17-[ADDRESS_1145245] 
This protocol and the vaccine tested are covered under the Public Readiness and Emergency 
Preparedness  (PREP)  Act. The PREP  Act provides  compensation  to participants  in the event  of 
serious physical injury or death caused by [CONTACT_92225], and liability protection 
for persons conducting the clinical study and the manufacturer of the drug or vaccine.  
The vaccine used in this clinical study is covered as a countermeasure under the  PREP Act. This 
provides  immunity  for covered  persons  (including  manufacturers,  distributers,  program  planners, 
and other qualified persons who prescribe, administer, or dispense the vaccine) from tort 
liability, unless the injury was caused by [CONTACT_154389].  
 
The Act authorizes an emergency fund administered by [CONTACT_825864] (CICP). The CICP 
provides  compensation  to eligible  individuals  who suffer  specified  injuries  from  administration 
or use of a countermeasure  pursuant  to the declaration.  Any requests  for compensation  must  be 
filed with the CICP within 1 year of administration or use of the countermeasure. For more 
information please visit the CICP website at http://www.hrsa.gov/cicp/. It is also advised 
participants  consult  an attorney  in the event  they suffer  a serious  injury  and wish  to file a claim 
for compensation with the CICP.  
 
 
Secondary  Use of Stored  Specimens  
 
Participants who agree to participate in this trial will have venous blood collected for clinical 
safety laboratory evaluations, stored samples for use in the evaluation of suspected or confirmed 
PI[INVESTIGATOR_106279], and serological immunology assays. Any excess aliquo ts of serum available from 
blood samples, once protocol -defined assays are completed, will be stored for use in new or 
different immunological laboratory tests, to provide information for the development of new 
vaccines, or for the studies of anthrax or ot her infections. These aliquots, other than the blood 
drawn  specifically  for evaluation  of PI[INVESTIGATOR_106279],  are derived  from  blood  already  collected  as part of 
the study, not from additional blood volumes collected solely for the purpose of secondary use.  

DMID  Protocol  17-[ADDRESS_1145246] and approval from DMID, may be 
shared with investigators at the participating VTEU site, with other investigators or designated 
research laboratories for purposes of conducting additional immunological assessments other 
than PP analysis. The IRB will approve the use and bre adth of secondary use specimens. DMID 
would authorize shipment from the DMID CMS. There are no benefits to participants in the 
collection, storage, and secondary research use of their samples/specimens. Secondary research 
use samples/specimens will not be sold or used directly for production of any commercial 
product.  No genetic  tests will be performed  on stored/secondary  use specimens.  Samples  will be 
stored indefinitely at an NIH -designated research storage facility.  
 
Each sample/specimen will be encoded (labeled) only with a barcode and a unique tracking 
number  to protect  participant  confidentiality.  Reports  from  secondary  research  studies  performed 
using participants’ samples/specimens will NOT be kept in their health records and will not be 
reported to the participant. Assaying of secondary use specimens and providing reports of 
secondary use results will not be done during this protocol.  
 
Participants  will be asked  to consent  to the secondary  research  use of excess/residual  specimens 
as an option, when they first consent to study participation. If they choose not to provide 
permission  for excess  blood  and secondary  use, they will still remain  eligible  for randomization 
and enrollment into the study.  
 
Participants who at first choose to allow for secondary use of excess/residual aliquots may 
withdraw  permission  to use samples  for secondary  use at any time,  even  if they do not withdraw 
consent for participation.  Samples stored for secondary use will not be assayed for secondary 
use tests during this study. Participants who choose to withdraw permission for secondary use 
will need to contact [CONTACT_825865]. Documentatio n will be completed that outlines the reason for 
withdrawal of permission for secondary use of samples.  
 
There are no additional risks accrued by [CONTACT_825866]. The scope of tests to be performed is similar in nature and detail to the 
immunologic  tests already  proposed  in this protocol.  The alternative  is for participants  to choose 
not to allow for secondary use of their stored specimens.  
DMID  Protocol  17-[ADDRESS_1145247] 
data transfer. Data will be entered into an eCRF via a 21 CFR 11 -compliant Internet Data Entry 
System provided and maintained by [CONTACT_825867] C enter (SDCC). The data 
system  includes  password  protection  and internal  quality  checks,  such as automatic  range  checks, 
to identify data that appear inconsistent, incomplete, or inaccurate.  
 
For any forms requiring paper, data collection forms (DCFs) will be derived from the eCRF and 
provided by [CONTACT_825868]. All 
DCFs  will be completed  in a neat,  legible  manner  to ensure  accurate  interpretation  of data. Black 
or blue ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making a change or 
correction, research staff members will cross out the original entry with a single line and initial 
and date the change. They will not erase, overwrite, or use correction fluid or tape on the 
original.  
 
Electronic  case report  forms  will serve  as the source  documents  for data collected  and will be 
created by [CONTACT_825869].  
 
The sponsor and/or its designee  will provide guidance to the site PIs and other study personnel 
on making  corrections  to the DCFs  and eCRF.  Details  on data handling  procedures,  procedures 
for data monitoring, and instructions for use of the system and completion of the eCRFs are 
provided in the study MOP, eCRF Instructions, and Advantage eClinical User’s Guide.  
 
Data  Management  Responsibilities  
 
All eCRFs  and laboratory  reports  will be reviewed  by [CONTACT_825870], 
who will ensure that they are accurate and complete. AEs will be recorded on the appropriate 
eCRF, assessed for severity and relationship, and reviewed by [CONTACT_7880] [INVESTIGATOR_29353] - 
investigator.  
 
Data  collection  is the responsibility  of the study  personnel  at the  participating  VTEU  site under 
the supervision of the site PI. During this trial, the site PI [INVESTIGATOR_825802].  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
94  
  
The SDCC  for this trial will be responsible  for data management,  quality  review,  analysis,  and 
reporting of the study data.  
 
Data  Capture  Methods  
 
Clinical (including, but not limited to, AE/SAEs, MAAEs, AESIs [PI[INVESTIGATOR_106279]], concomitant 
medications, medical history, physical assessments, and clinical laboratory values), 
reactogenicity, and immunogenicity data will be entered into a [ADDRESS_1145248] 
protection and internal quality checks, such as automatic range checks, to identify data that 
appear inconsistent, incomplete or inaccurate. Clinical and reactogenicity data will be entered 
directly onto eCRFs by [CONTACT_44518].  
 
Types  of Data  
 
Data  for this trial will include  clinical,  safety,  and outcome  measures  (e.g.,  clinical  laboratory 
values, and reactogenicity and immunogenicity data).  
 
Timing/Reports  
 
The final CSR will be completed after the last participant's last visit is completed, the final 
clinical  database  including  all long-term safety  follow -up data is cleaned,  monitored  and locked, 
and all primary and secondary immunogenicity data are available. There are no planned 
exploratory immunogenicity endpoints. If any are added via protocol amendment, then the 
additional exploratory immunogenicity endpoint data not available at the time of CSR 
preparation may be included in an addendum to the CSR.  
 
A formal statistical analysis plan will be developed, finalized, and submitted to the  FDA, prior  to 
unblinding  for any analysis,  which  defines  the analyses  to be included  in the expedited  report  and 
the final CSR.  
 
Additional  statistical  reports  may be generated  as deemed  necessary  and appropriate  by [CONTACT_122830]. 
Safety and immunogenicity summary reports may be generated for the SMC.  
 
After the final CSR is complete, and upon request and DMID approval, the SDCC will provide 
the participating VTEU site with a summary of results by [CONTACT_692346]/or participant 
treatment  assignment.  In this regard,  the participating  VTEU  site requesting  such information  to 
share with participants must do so in accordance with IRB requirements.  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
95  
  
Study  Records  Retention  
 
Study records and reports, including, but not limited to, eCRFs, source documents, ICFs, and 
study drug disposition records shall be maintained for 2 years after a marketing application is 
approved for the drug for the indication for which it is being investigated; or, if no application is 
to be filed or if the application  is not approved  for the drug,  until 2 years  after the investigation  is 
discontinued and the FDA has been notified. These documents will be retained for a longer 
period, however, if required by [CONTACT_427]. ICFs for secondary research use will be 
maintai ned as long as the sample/specimen exists.  
 
No records  will be destroyed  without  the written  consent  of the sponsor.  It is the responsibility  of 
the sponsor to inform the site PI [INVESTIGATOR_135830]. The 
participating VTEU sites must contact [CONTACT_295069].  
 
Protocol  Deviations  
 
A protocol deviation is any noncompliance with the study protocol, GCP, or protocol -specific 
MOP  requirements.  The noncompliance  may be either  on the part of the participant,  the site PI, 
or other study personnel. As a result of protocol deviations, corrective actions are to be 
developed by [CONTACT_3483].  
 
These  practices  are consistent  with ICH E6 GCP guidelines:  
 
4.[ADDRESS_1145249] be promptly reported to DMID, via the SDCC’s Advantage eClinicalSM. 
 
All protocol deviations, as defined above, must be addressed on the appropriate eCRF. A 
completed  copy  of the Protocol  Deviation  eCRF  must  be maintained  in the regulatory  file as well 
as in the participants’ chart. Protocol deviations must be sent to the IRB in accordance with IRB 
requirements. The site PI [INVESTIGATOR_294990].  

DMID  Protocol  17-[ADDRESS_1145250] submitted for them to the National 
Library of Medicine’s PubMed Central ( http://www.ncbi.nlm.nih.gov/pmc/ ) an electronic 
version of their final, peer -reviewed manuscripts upon acceptance for publication, to be made 
publicly available no later than [ADDRESS_1145251] be accessible to the public on PubMed Central no later than 12 
months after publication.  
 
Refer  to: 
 
• NIH Public  Access  Policy,  http://publicaccess.nih.gov/  
 
• NIH Office  of Extramural  Research  (OER)  Grants  and Funding, 
http://grants.nih.gov/grants/oer.htm  
 
As of January 2018, all clinical trials supported by [CONTACT_12242].gov,  no later than [ADDRESS_1145252] applied for certification of delay ed posting.  
 
As part of the result  posting  a copy  of this protocol  (and its amendments)  and a copy  of the 
Statistical Analysis Plan will be posted on ClincialTrials.gov.  
 
For this clinical  trial, the responsible  party  is DMID  which  will register  this trial and post results. 
The responsible party does not plan to request certification of delayed posting.  
 
 
Refer  to: 
 
• Public  Law 110-85, Section  801, Clinical  Trial  Databases  
 
• 42CFR11  
 
• NIH NOT -OD-16-[ADDRESS_1145253] Africa --Connecticut, 2007. MMWR Morb Mortal Wkly Rep 2008;57:628 - 
31. 
2. Inglesby  [CONTACT_67382], Henderson  DA, Bartlett  JG, et al. Anthrax  as a biological  weapon:  medical 
and public  health  management.  Working  Group  on Civilian  Biodefense.  JAMA  1999;281:[ADDRESS_1145254], Bell BP, et al. Investigation  of bioterrorism -related 
anthrax, [LOCATION_002], 2001: epi[INVESTIGATOR_257618]. Emerg Infect Dis 2002;8:[ADDRESS_1145255] challenge by [CONTACT_825871]. Vaccine 2001;19:3241 -7. 
5. Brachman PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field 
Evaluation  of a Human  Anthrax  Vaccine.  Am J Public  Health  Nations  Health  1962;52:632 -45. 
6. Wright JG, Quinn CP, Shadomy S, Messonnier N, Centers for  Disease  C, Prevention. 
Use of anthrax  vaccine  in the United  States:  recommendations  of the Advisory  Committee  on 
Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010;59:1 -30. 
7. Hopkins RJ, Daczkowski NF, Kaptur PE, et al. Randomized, double -blind, placebo - 
controlled,  safety  and immunogenicity  study  of 4 formulations  of Anthrax  Vaccine  Adsorbed 
plus CPG 7909 (AV7909) in healthy adult volunteers. Vaccine 2013;31:3051 -8. 
8. Minang  JT, Inglefield  JR, Harris  AM, et al. Enhanced  early  innate  and T cell-mediated 
responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909). 
Vaccine 2014;32:6847 -54. 
9. Rynkiewicz  D, Rathkopf  M, Sim I, et al. Marked  enhancement  of the immune  response  to 
BioThrax(R)  (Anthrax  Vaccine Adsorbed) by  [CONTACT_257734]9  agonist  CPG  7909  in healthy  volunteers. 
Vaccine 2011;29:[ADDRESS_1145256] 
1992;34:582 -4. 
11. Ramos  JA. Venipuncture -related  lateral  antebrachial  cutaneous  nerve  injury:  what  to 
know? Braz J Anesthesiol 2014;64:131 -3. 
12. Atanasoff  S, Ryan  T, Lightfoot  R, Johann -Liang  R. Shoulder  injury  related  to vaccine 
administration (SIRVA). Vaccine 2010;28:[ADDRESS_1145257] -exposure prophylaxis in healthy adults. 
Vaccine 2016;34:2096 -105. 
14. Segal  BM, Chang  JT, Shevach  EM. CpG  oligonucleotides  are potent  adjuvants  for the 
activation of autoreactive encephalitogenic T cells in vivo. J Immunol 2000;164:[ADDRESS_1145258] Dis 2008;46:1310 -4. 
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
98  
  
16. Cooper  CL, Davis  HL, Angel  JB, et al. CPG  7909  adjuvant  improves  hepatitis  B virus 
vaccine seroprotection in antiretroviral -treated HIV -infected adults. AIDS 2005;19:[ADDRESS_1145259], Martin  LB, Shaffer  D, et al. Phase  1 trial of the Plasmodium  falciparum  blood 
stage vaccine MSP1(42) -C1/Alhydrogel with and without CPG 7909 in malaria naive adults. 
PLoS One 2010;5:e8787.  
18. Mullen  GE, Ellis RD, Miura  K, et al. Phase  1 trial of AMA1 -C1/Alhydrogel  plus CPG 
7909: an asexual blood -stage vaccine for Plasmodium falciparum malaria. PLoS One 
2008;3:e2940.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
99  
  
18 APPENDICES  
 
Appendix  A: Schedule  of Study  Procedures  and Evaluations  
 
Appendix  B: Adverse  Events  of Special  Interest  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
100  
  
SCHEDULE  OF STUDY  PROCEDURES  AND 
EVALUATIONS  
 
Study  Visit  (V) 0 1 2 3 4 5 6 7 8 Early  
Termination  
Study  Day# pre 1 8 15# 22# 29# 64# 195# 380#  
Window  Open  -28 1 8 15 22 27 60 188 373  
Window  Close  -2 1 11 18 25 31 68 202 387  
Study  Week  pre 1 1 2 3 4 9 28 54  
Activity/Procedure            
Inform  prospective  participant  about  study  details1 X          
Obtain  informed  consent,  HIPAA  authorization,  
enroll2 X          
Obtain,  record,  update  demographics,  medical  
history, concomitant medications3 X X X X X X X X X X 
Perform  physical  examination4 X X X X X X X X X X 
Collect  blood/urine  for eligibility  or post- 
vaccination safety5 X     X    X 
Perform  pregnancy  test6 X X  X       
Perform  12-lead electrocardiogram7 X          
Review  eligibility  criteria  or criteria  for 
subsequent  vacination8 X X  X       
Perform  randomization9  X         
Vaccinate10  X  X       
Perform post-vaccination reactogenicity  
assessment,  instruct  on eMemory  Aid, & provide  
study related materials11  X  X       
Counsel  on avoidance  of pregnancy12 X X X X X X X    
Review  memory  aid (solicited  AEs/reactogenicity)  
& confirm data13   X  X      
Examine  study  vaccination  site14   X  X     X 
Collect  blood  – Toxin  Neutralization  Assay  
(TNA) and anti -PA IgG by [CONTACT_6428]15  X X X X X X X X X 
Collect  blood  – to be stored  for use if PI[INVESTIGATOR_825803]16 X          
Perform  assessment17 of non-serious  unsolicited  
AEs  X X X X X X   X 
Perform  SAE,  MAAE,  and AESI  assessment18  X X X X X X X X X 
 
# Note  that all visits  after Visit  3 (target  Day 15, second  vaccination) are  based  on the day that Visit  [ADDRESS_1145260] demographics, medical history, and 
concomitant medications. At screening and the Day 1 visit, these activities will be performed for the 
purposes  of determining  eligibility  and baseline  health  status.  On subsequent  visits,  updates  to the medical 
history  and medications  will be  collected  and recorded to  evaluate  for AEs. Concomitant  medications  will 
be recorded routinely through Day 64. After Day 64, only concomitant medications (new and updates to 
previously reported ones) that are taken in relation to MAAEs, SAEs, and AESIs (PI[INVESTIGATOR_106279]) will be 
recorded.  
4. At screening, a more detailed physical examination will be performed to determine eligibility and any 
baseline findings. This exam includes a height and weight for the determination of Body Mass Index 
(BMI).  At Day 1 and at subsequent  visits,  a physical  examination  will only be  performed  if the participant 
reports a symptom warranting an exam. The screening exam will be “detailed”; the subsequent exams, 
when  needed,  will be “targeted”.  The screening  exam,  Day 1, Day 15, and ET visits  will also include  vital 
signs (blood pressure, heart rate, oral temperature). Vital signs may be repeated at the discretion of the 
clinician, up to [ADDRESS_1145261] (β hCG) will be sent with the screening laboratory specimens and a point -of-care 
urine pregnancy test will be performed on Days 1 and 15, with results determined to be negative before 
randomization  and vaccination.  Should  Visit  3 (second  vaccination)  occur  after Day 15, the pregnancy  test 
will be performed on the day of the visit, with results determined to be negative before vaccination.  
7. A routine  12-lead electrocardiogram  will be performed  at screening.  It will be read by [CONTACT_825872], reviewed by [CONTACT_093], and officially read by a cardiologist. Participants with clinically 
significant abnormalities will be excluded. Adjustments may be made while the ECG is being performed, 
but once it is complete, no repea t ECGs will be performed unless the reviewing cardiologist requires a 
repeat study for clarification. No repeat ECGs will be performed after vaccination.  
8. Prior to randomization and enrollment, the PI [INVESTIGATOR_022]/her delegate will review all eligibility criteria and 
record  his/her  determination.  Prior  to the second  dose on Day 15 (or  as late as Day 18), the PI [INVESTIGATOR_022]/her 
delegate will review all criteria for subsequent dosing and record his/her determination.  
9. Upon  determination  of eligibility,  the pharmacy  will be notified  to proceed  with randomization  and 
preparation of the vaccine either as the liquid formulation or lyophilized formulation.  
10. A pre -administration reactogenicity assessments will be performed immediately prior to study vaccination 
to establish  baseline.  The participant  will be vaccinated  intramuscularly,  in the deltoid  of the arm chosen  by 
[CONTACT_2299], by [CONTACT_825873].  
11. In the [ADDRESS_1145262]  solicited  adverse  events  (reactogenicity) on 
Days 1 through 8 and Days 15 through 22, inclusive. Should Visit 3 (second vaccination) occur after Day 
15, the reactogenicity period will be adjusted to collect a full [ADDRESS_1145263] information, ruler, and thermometer, will be 
provided.  
12. Women  of childbearing  potential  will be counseled  to avoid  pregnancy  until 60 days after the second  (final) 
vaccination, i.e., Day 75 if Visit 3 occurs on Day 15.  
13. In the 7 days following  vaccination (Days  1 through  8, inclusively  and Days  15 through  22, inclusively;  or 
adjusted,  as described  above,  should  second  vaccination  occur  after Day 15), during  which  the participants 
will be directly entering their reactogenicity profiles through a secure web portal, the study team will be 
reviewing the entries, answering questions, and contact[CONTACT_825874]. 
On Days 8 and 22 (or 7 da ys after the second vaccination, if the second vaccination occurs after Day 15), 
when the post -vaccination diaries will have been completed, the study team will confirm all en tries. At 
these visits, the participant will also be asked about unsolicited AEs. If solicited AEs persist in Day 8 or 
Day 22 (beyond the seventh day after second vaccination), they will be followed to resolution.  
14. The site of the vaccination  will be examined  and findings  recorded  on the appropriate  CRF.  
DMID  Protocol  17-[ADDRESS_1145264]  anthrax.  It is 
performed on serum. ELISA will also be performed, to measure the concentration of anti -PA IgG. On 
vaccination days (Visits 1 and 3), these will be collected prior to vaccination.  
16. Blood  will be collected  for storage  in case the  participant  develops  signs  and/or  symptoms  of a PI[INVESTIGATOR_106286].  
17. Information on unsolicited AEs  that are not  serious  will be collected from the time of the first  study 
vaccination  to the Day 64 visit (or the Day as determined  in an adjusted  schedule,  should  the second 
vaccination, Visit 3, occur after Day 15).  
18. Information on SAEs, MAAEs, and AESIs will be collected from the time of the first study vaccination to 
the Day 380 visit (which  may be adjusted,  should  the second  vaccination,  Visit  3, occur  after Day 15). The 
only AESIs  for this study  are potentially  immune  mediated  diseases (PI[INVESTIGATOR_106279]).  If an AESI  is reported,  the 
participant will be asked to have an evaluation performed.  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
103  
  
 
 
PI[INVESTIGATOR_106279]:  ADVERSE  EVENTS  OF SPECIAL  INTEREST  
 
Gastrointestinal  disorders  
 
• Celiac  disease  
• Crohn’s  disease  
• Ulcerative  colitis  
• Ulcerative  proctitis  
 
Liver  disorders  
 
• Autoimmune cholangitis  
• Autoimmune hepatitis  
• Primary  biliary  cirrhosis  
• Primary  sclerosing  cholangitis  
 
Metabolic  diseases  
 
• Addison’s  disease  
• Autoimmune  thyroiditis  (including  Hashimoto  thyroiditis)  
• Diabetes  mellitus  type I 
• Grave’s  or Basedow’s  disease  
 
Musculoskeletal  disorders  
 
• Antisynthetase  syndrome  
• Dermatomyositis  
• Juvenile  chronic  arthritis  (including  Still’s  disease)  
• Mixed  connective  tissue  disorder  
• Polymyalgia  rheumatic  
• Polymyositis  
• Psoriatic  arthropathy  
• Relapsing  polychondritis  
• Rheumatoid  arthritis  
• Scleroderma,  including  diffuse  systemic  form  and CREST  syndrome  
• Spondyloarthritis,  including  ankylosing  spondylitis,  reactive  arthritis  (Reiter’s 
Syndrome) and undifferentiated spondyloarthritis  
• Systemic  lupus  erythematosus  
• Systemic  sclerosis  
 
Neuroinflammatory  disorders  

DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
104  
  
• Acute  disseminated  encephalomyelitis,  including  site-specific  variants  (e.g.,  non- 
infectious encephalitis, encephalomyelitis, myelitis, myeloradiculomyelitis)  
• Cranial  nerve  disorders,  including  paralyses/paresis  (e.g.,  Bell’s  palsy)  
• Guillain -Barré  syndrome,  including  Miller  Fisher  syndrome  and other  variants  
• Immune -mediated  peripheral  neuropathies  and plexopathies,  including  chronic 
inflammatory  demyelinating  polyneuropathy,  multifocal  motor  neuropathy  and 
polyneuropathies associated with monoclonal gammopathy  
• Multiple  sclerosis  
• Narcolepsy  
• Optic  neuritis  
• Transverse  myelitis  
• Myasthenia  gravis,  including  Eaton -Lambert  syndrome  
 
Skin  disorders  
 
• Alopecia  areata  
• Autoimmune  bullous  skin diseases,  including  pemphigus,  pemphigoid  and dermatitis 
herpetiformis  
• Cutaneous  lupus  erythematosus  
• Erythema  nodosum  
• Morphoea  
• Lichen  planus  
• Psoriasis  
• Sweet’s  syndrome  
• Vitiligo  
 
Vasculitides  
 
• Large  vessels  vasculitis  including:  giant  cell arteritis  such as Takayasu’s  arteritis  and 
temporal arteritis  
• Medium sized and/or small vessels vasculitis including: polyarteritis nodosa, 
Kawasaki’s disease, microscopic polyangiitis, Wegener’s granulomatosis, Churg - 
Strauss syndrome (allergic granulomatous angiitis), Buerger’s disease 
thromboangiitis obliterans, n ecrotizing vasculitis and anti -neutrophil cytoplasmic 
antibody  (ANCA)  positive  vasculitis  (type  unspecified),  Henoch - Schonlein  purpura, 
Behcet’s syndrome, leukocytoclastic vasculitis  
 
Others  
• Antiphospholipid syndrome  
• Autoimmune  hemolytic  anemia  
DMID  Protocol  17-0093  
Anthrax  AV7909  Liquid  vs Lyophilized  Version  4.0 
11 Jul  2022  
105  
  
• Autoimmune  glomerulonephritis  (including  IgA nephropathy,  glomerulonephritis 
rapi[INVESTIGATOR_10480], membranous glomerulonephritis, membranoproliferative 
glomerulonephritis, and mesangioproliferative glomerulonephritis)  
• Autoimmune myocarditis/cardiomyopathy  
• Autoimmune parotitis  
• Autoimmune thrombocytopenia  
• Good  pasture  syndrome  
• Idiopathic  pulmonary  fibrosis  
• Pernicious  anemia  
• Raynaud’s  phenomenon  
• Sarcoidosis  
• Sjögren’s  syndrome  
• Stevens -Johnson  syndrome  
• Uveitis  